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CHAPTER I 
 
INTRODUCTION 
 
The tissue repair process following a myocardial infarction 
Coronary heart disease resulting in myocardial infarction (MI) is the 
leading cause of death in both men and women, contributing to 1 in 3 deaths 
(Mozaffarian et al., 2015). Each year about 735,000 people in the U.S. have an 
MI and most suffer irreversible tissue damage, leading to ventricular remodeling, 
hypertrophy, deficient contractility, dilatation, and eventually heart failure (HF) 
(McMurray, 2010; Braunwald, 2015).  Despite the fact that overall death rates 
due to cardiovascular disease have decreased 30% over the last few decades, 
the number of deaths caused by end-stage heart failure has not changed, 
demonstrating a need for improving treatments following an acute cardiac injury 
such as an MI (Braunwald, 2015).   
 
Overview 
Following an MI, the adult heart undergoes a sequence of molecular and cellular 
events that delineate the different stages of tissue repair (Saxena et al., 2015) 
(Figure 1). Cardiomyocytes within infarcted myocardium begin to die via necrosis 
and apoptosis within minutes after coronary artery occlusion (Itoh et al., 1995; 
Konstantinidis et al., 2012; Reimer and Jennings, 1979). Toxic products and 
signals, known as danger associated molecular patterns or DAMPS, released 
from dying cells induce endothelial cell adhesion proteins, as well as cytokines 
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and chemokines, to recruit inflammatory cells that remove tissue debris as well 
as secrete proteases such as matrix metalloproteinase (MMPs) to degrade 
extracellular matrix (Timmers et al., 2012; Frangogiannis, 2014). After debris is 
cleared, the gap is filled with granulation tissue that is composed of proliferating 
cells, mainly endothelial cells that form new capillaries, and myofibroblasts that 
secrete collagen and other matrix proteins (Boudoulas and Hatzopoulos, 2009; 
Frangogiannis, 2012). Two to three weeks after the MI, the infarct tissue begins 
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to mature into a dense, cross-linked, collagen-based scar (Virag and Murry, 
2003). These well-documented stages that comprise the tissue repair process 
are highly regulated in a spatiotemporal manner. However, what regulates these 
processes both temporally and spatially is not entirely understood.  We have 
recently demonstrated that canonical Wnt signaling activation after MI attenuates 
fibrosis and promotes arteriole formation and cardiogenesis, suggesting that 
developmental pathways, critical for embryonic cardiac development, are re-
activated after injury in the adult heart to regulate tissue repair (Aisagbonhi et al., 
2011; Paik et al., 2015).  
Activated inflammatory cells that infiltrate the heart during the initial stages 
of the tissue repair process can damage surrounding, relatively healthy tissue by 
inducing secondary apoptosis and necrosis through the secretion of pro-
inflammatory cytokines such as TNFα, and by secreting matrix degrading 
proteins, thereby expanding the size of the initial injury (Entman et al., 1992). 
Overactive or unresolved inflammation delays and weakens scar formation; 
preventing proper wound healing (Kattman et al., 2011; Kruithof et al., 2006; 
Lenhart et al., 2011; Zhang et al., 2014). As a result, deregulated inflammation in 
MI patients can worsen LV dilative remodeling and systolic function, leading to 
HF (Frangogiannis, 2014).  Therefore a better understanding of how the 
inflammatory process is regulated is critical for generating therapies that could 
lead to the improvement of the prognosis of heart failure.   
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Inflammatory phase of recovery 
The inflammatory phase begins with the accumulation of DAMPs, the 
molecules released by dead or dying cells or generated from the damaged 
extracellular matrix examples of which include low molecular weight hyaluronic 
acid and fibronectin fragments.  These DAMPs then serve as ligands to activate 
the complement cascade and Toll-Like receptors. The complement cascade 
consists of the classical cascade, which activates immunoglobins, and the lectin 
cascade, which is traditionally associated with a response to microbials, all of 
which activate C3, leading to the subsequent activation of phagocytosis and 
neutrophil infiltration.  
Free radicals present in the injury area such as reactive oxygen species 
induce the expression of cytokines and chemokines such as TNFα and IL-1β by 
endothelial cells, mast cells, and cardiac cells (Figure 2A).   These cytokines in 
turn, induce the expression of other chemokines (i.e. MCP-1, IL-6, SDF-1) and 
cell adhesion molecules present on endothelial cells through NFκB and 
JAK/STAT pathways activation (Christia and Frangogiannis, 2013; 
Frangogiannis, 2012; Ma et al., 2013; Zhang et al., 2014). In parallel, DAMPS 
also activate the NFκB pathway by activating Toll-like receptors or TLRs (Akira 
and Takeda, 2004; Timmers et al., 2012). NFκB signaling also induces the 
expression of pro-inflammatory cell adhesion molecules such as E-selectin and 
VCAM (vascular cell adhesion molecule), which are required for the capture, 
rolling, adhesion, and extravasation of circulating leukocytes through the 
endothelial cell layer to the site of injury (Figure 2B).   
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Platelets are the first responding population of cells to enter the site of 
injury and act to provide a provisional matrix and secrete pro-inflammatory 
cytokines such as IL-1β, as well as activate the complement cascade.  Leukocyte 
cell populations then enter the scene, beginning with neutrophils, followed by the 
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pro-inflammatory monocytes/macrophages, and finally adaptive immune cell 
populations such as regulatory T cells, B cells, and Natural Killer cells 
(Frangogiannis, 2008; Kain et al., 2014; Yan et al., 2013).  These immune cell 
populations are recruited from a splenic reservoir through Angiotensin II 
activation, the bone marrow, and heart-draining lymph nodes (Kain et al., 2014; 
Ma et al., 2013; Swirski and Nahrendorf, 2013; Weirather et al., 2014; Zhang et 
al., 2014) They act to clear the cellular debris, phagocytose dead cells, secrete 
MMPs, release pro-inflammatory cytokines. 
Resolution of the inflammatory response is a dynamic and active process.  
The sequence of events that occurs during resolution is initiated by apoptotic 
neutrophils.  These neutrophils express “find me” and “eat me” signals, which 
include fractalkine, ATPs, and lactoferrin; or annexin and phosphatidylserine 
respectively.  The release of these proteins causes an expansion of the T-reg cell 
population as well as a phenotypic switch in macrophages, where they transition 
from a pro-inflammatory phenotype to a reparative phenotype. After this 
transition, macrophages no longer induce the expression of the pro-inflammatory 
cytokines, and instead, along with T-reg cells, secrete cytokines responsible for 
resolving inflammation, TGFβ1 and IL-10.  TGFβ1 induces the expression of 
matrix metalloproteinases (MMPs) that cleave both the CC and CXC families of 
chemokines and reduces cell-adhesion molecule expression.  Il-10 promotes the 
presence of chemokine receptors such as CCR1, CCR2, and CCR5 thereby 
trapping circulating cytokines, inhibits production of pro-inflammatory cytokines 
through mRNA de-stabilization, and contributes to matrix stabilization through the 
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induction of tissue inhibitor of MMPs (TIMPs) (Christia and Frangogiannis, 2013; 
Frangogiannis, 2012; Krishnamurthy et al., 2009; Ortega-Gómez et al., 2013; 
Zhang et al., 2014).  
Patients that exhibited increased levels of inflammatory biomarkers also 
had an increase in the extent of heart failure (Anzai et al., 1997; Frangogiannis, 
2014; Ma et al., 2013; Ørn et al., 2009; Zhang et al., 2014). Therefore due to the 
apparent therapeutic potential, previous clinical trials have attempted to down-
regulate the inflammatory response. However, the first trial using the 
glucocorticoid methylprednisolone actually had detrimental effects to the 
recovery of the patient group (da Luz et al., 1976).  As the understanding of the 
inflammatory process post-MI has improved, additional clinical trials have been 
attempted.  The ATTACH, RENAISSANCE, and the following larger trial 
RENEWAL used a recombinant TNFα receptor that prevented TNFα ligand-
receptor interactions.  These trials also led to increased morbidity and worse 
outcomes for those patients treated with the TNFα antagonist (Mann et al., 
2004).  Several trials took more specific approaches and targeted the leukocyte 
integrin CD11/CD18, following the success seen in animal models.   However 
this treatment did not result in a reduction of infarct size or an improvement in 
cardiac function in human patients (Baran et al., 2001; Faxon et al., 2002). Using 
an antibody that binds to a component of the complement cascade also resulted 
in no change in morbidity (APEX AMI Investigators et al., 2007; Granger et al., 
2003).  Most recently, intravenous immunoglobulin treatment was used in hopes 
to balance the cytokine response post-MI but also resulted in no change in infarct 
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size and cardiac function (Gullestad et al., 2013).  On the other hand, inhibitors of 
activated T-cells such as cyclosporine (Piot et al., 2008) and the P-selectin 
antagonist inclacumab (Tardif et al., 2013) did show promising results, indicating 
that modulating inflammation can be beneficial for cardiac repair after MI. 
Unfortunately, the benefits of cyclosporine use after MI could not be replicated in 
a larger clinical trial (Cung et al., NEJM 2015). Altogether, the clinical data 
underscore the need to better understand the mechanisms that regulate the 
inflammatory response after cardiac tissue injury. 
 
BMP signaling in cardiac development 
In order to gain insight into the molecular mechanisms that regulates the 
cardiac tissue repair process, the Hatzopoulos lab looked to pathways important 
for cardiac development that are often re-activated during tissue repair and 
regeneration.  One such pathway is the Bone Morphogenetic Protein (BMP) 
signaling pathway.  Originally discovered in the context of bone formation 
(Umulis et al., 2009), the pathway has since been extensively studied in the 
context of patterning and development using various models such as chicken 
embryos, mice, and zebrafish (Dudley et al., 1995; Furtado et al., 2008; 
Hammerschmidt et al., 1996; Jones et al., 1991; Luo et al., 1995; Schlange et al., 
2002; Weaver et al., 1999; Winnier et al., 1995; Wozney et al., 1988). 
Specifically, BMP signaling has been shown to play an important role during 
various stages of the complex cardiac development process and is necessary for 
the initiation of the cardiac gene program.  
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The process of cardiac differentiation begins with the formation of a linear 
cardiac tube.  The tube then undergoes a series of looping and jogging events in 
order to generate the 4-chambered heart (Figure 3).   
 
 
Each of these stages is highly regulated and requires different members and 
levels of the activated BMP pathway. In fact, Bmp2-/- mice are embryonic lethal 
and die shortly after heart tube formation, demonstrating that Bmp2 is essential 
for cardiac development to proceed (Zhang and Bradley, 1996). This is in part 
likely due to the fact that Bmp2 is responsible for inducing early cardiogenic 
differentiation of the mesoderm into myocardial and epicardial cell lineages, 
expression of cardiogenic transcription factors as well as Bmp10, and genes 
encoding various components of the contractile apparatus (Chen et al., 2004; 
Jain et al., 2015; Kattman et al., 2011; Kruithof et al., 2006; de Pater et al., 2012; 
Wang et al., 2007).  Bmp2 and Bmp4 are also required for atrial-ventricular canal 
and outflow tract formation (van Wijk et al., 2007).  
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BMP ligands and cardiac differentiation 
BMP signaling is responsible for the left-right asymmetry required for 
normal cardiac morphogenesis to occur.  This has been evidenced by its 
regulation of target genes such as Pitx2, promotion of cardiac chamber identity, 
and through the loss of jogging and looping events when it is inhibited. BMP 
ligands such as Bmp4, Bmp6, and Bmp7 are then again required for cardiac 
cushion formation through their regulation of cellular events such as endothelial 
to mesenchymal transition (EndMT), valve and ventricular septation, and 
endocardial cushion cell number (Kim et al., 2001; Liu et al., 2004; Ma et al., 
2005; McCulley et al., 2008; Solloway and Robertson, 1999).    
 
BMP antagonists and cardiac development 
It is also clear that it is not just the presence, but also the level of BMP 
signaling that is necessary for normal cardiac development. In fact, it has been 
extensively shown that the level of active canonical BMP signaling directly affects 
cardiac chamber identity and proportion (Chocron et al., 2007; Furtado et al., 
2008; Lenhart et al., 2011; Marques and Yelon, 2009).  The regulation of active 
BMP signaling is done primarily through the activity of BMP antagonists. 
Evidence suggests that these proteins are also important for cardiac 
developmental processes.  For example, mice that lack the BMP antagonist 
Noggin exhibit a thicker myocardium that is rescued with the addition of Bmp4 
(Choi et al., 2007).  Therefore, it appears that cardiac development requires 
tightly regulated BMP signaling activity through the action of antagonists.   
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BMP signaling in cardiac repair and inflammation 
BMP signaling is also induced after ischemic injury in the adult mouse 
heart.   Previous work has shown that Bmp4 expression is induced in mice after 
pressure overload, angiotensin II production, or a permanent coronary artery 
ligation and was implicated in regulating cardiomyocyte apoptosis during 
ischemia/reperfusion injury through the non-canonical JNK pathway.  Treatment 
with the endogenous antagonist Noggin, as well as chemical inhibitors 
dorsomorphin and DMH1 reduced mouse infarct size and cardiac hypertrophy. 
BMP4, and BMP receptors BMPR1a and BMPRII, are also expressed in human 
cardiac tissue during end-stage heart failure or ischemic heart disease (Derwall 
et al., 2012; Morrell et al., 2015; Pachori et al., 2010; Sun et al., 2013; Wu et al., 
2014).   Bmp2 levels are significantly increased specifically in the myocardium 
and not in the serum, which was confirmed using histological analyses that 
showed strong induction of Bmp2 in the peri-infarct cardiomyocytes (Chang et 
al., 2008). However the exact role of BMP signaling in cardiac tissue repair and 
how BMP signaling is regulated after cardiac injury is not well understood.   
Previous studies have also linked BMP ligands to the stimulation of the 
pro-inflammatory phenotypes.  The pro-inflammatory cytokine TNFα induces 
BMP2 expression via mRNA stabilization and transcriptional up-regulation in an 
NFκB dependent manner.  This occurs via the NFκB binding sites located within 
the promoter region of BMP2 (Feng et al., 2003; Fukui et al., 2006).  Shear stress 
and pressure overload leads to the BMP driven adhesion of leukocytes to 
endothelial cells in vitro (Csiszar et al., 2005, 2006; Helbing et al., 2011; Sorescu 
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et al., 2003; Sucosky et al., 2009).  Likewise, BMP signaling has been associated 
with promotion of inflammation in models of atherosclerosis and with anemia 
caused by chronic inflammatory conditions.  For example, Bmp2 and Bmp4 
produced by vascular smooth muscle cells in atherosclerotic lesions induce 
monocyte chemotaxis through BmpRII (Chen et al., 2004; Sucosky et al., 2009; 
Pi et al., 2012; Simões Sato et al., 2014; Steinbicker et al., 2011; Zhao et al., 
2013; Mayeur et al., 2014).  Conversely, BMP antagonists such as BMPER and 
Gremlin 1 in the context of atherosclerosis, and Noggin in the aortic valve (AV) 
leaflet and in diabetic mice, can inhibit inflammation by reducing the expression 
of pro-inflammatory cell adhesion molecules (Koga et al., 2013; Pi et al., 2012; 
Sucosky et al., 2009) and administration of chemical inhibitors of BMP signaling 
such as LDN-193189 and dorsomorphin reduced vascular inflammation and 
atherosclerosis (Derwall et al., 2012; Helbing et al., 2011; Morrell et al., 2015; 
Saeed et al., 2012).  
 
BMP signaling 
Bone Morphogenetic Proteins (BMPs) belong to a subclass of the 
Transforming Growth Factor β (TGF-β) superfamily of heterodimeric secreted 
ligands. They contain a cystine knot structure common to this family of proteins. 
BMP ligands bind to hydrophobic type I and type II receptors, leading to 
phosphorylation in the GS box of the N-terminal kinase domain and activation of 
the type I receptor by its type II partner.  When BMP dimers bind to their 
heterotetrameric receptor complexes, the type I receptor binds to what is called 
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the wrist epitope of the BMP ligands and the type II receptors binds to the 
knuckle region.   Type I receptors are often referred to as activin receptor-like 
kinase (ALK). The type I receptors fall into 2 categories based on structural 
similarity and have distinct binding properties conferring signal specificity. For 
example BMP2/4 specifically bind to type I receptors ALK3/6 (Bragdon et al., 
2011; Lowery and de Caestecker, 2010; Miyazono et al., 2010; Sieber et al., 
2009) (Figure 4).   
 
Canonical BMP signaling occurs through SMADs 
Activated type I receptors phosphorylate SMAD1/5/8 at the SXS motif at 
the C-terminus, leading to the formation of a complex with SMAD4 and 
subsequent translocation of the complex to the nucleus (Euler-Taimor and  
Heger, 2006).  SMAD proteins contain two homology domains, mad homology or 
MH1 and MH2.  MH1 contains the nuclear localization signal as well as the DNA   
binding domain, whereas MH2 interact with the Type I receptor.  Smad 
complexes then bind DNA at AGAC where they regulate expression of target 
genes such as the ID family of transcriptional repressors (Hinck, 2012; Yadin et 
al., 2015).  ID’s are inhibitors of DNA binding and thereby inhibit the   
differentiation of certain cell lineages.  They belong to the helix-loop-helix family 
of transcription factors, however they lack the DNA-binding domain. Instead, they 
associate with other members of the family and prevent their binding to DNA or 
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from forming active heterodimers.  They most commonly interact with enhancer 
or E-box proteins that bind to the enhancer region located upstream transcription 
start sites (ID family of HLH proteins) (Miyazono et al., 2005).  In addition to 
canonical signaling, there is also a branch of non-canonical signaling, where 
MAPKs such as JNK and ERK are activated in lieu of SMADs (Sieber et al., 
2009).   
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BMP antagonists 
BMP signaling is modulated in the extracellular space by a large number 
of secreted, structurally diverse antagonists, such as Chordin, Noggin and 
members of the DAN family (Yanagita, 2005).  These antagonists also contain 
the cystine knot structure common in the ligands themselves and predominantly 
act by binding to the BMP ligands and thereby prevent ligand binding to their 
receptors. Namely, the large protein members such as Noggin and BMPER bind 
to both the type I and type II receptors binding domains present on the BMP 
ligands.  However, a unique form of antagonism exists in the Chordin, Tolloid, 
and Twisted gastrulation (Tsg) system.  Intact Chordin forms a complex with Tsg 
and BMP to inhibit BMP.  Tolloid cleaves Chordin and twisted gastrulation’s 
presence ensures this cleavage, freeing BMPs to interact with their receptors 
(Groppe et al., 2002; Umulis et al., 2009; Walsh et al., 2010; Zhang et al., 2008).  
Besides extracellular antagonist interactions, other modes or models of 
antagonism are thought to occur.  The exchange model occurs when low 
concentrations of the antagonist actually provides BMP ligands to the receptors 
and prevent any non-specific binding, whereas high concentrations sequester 
ligands.  The sink-source model, where BMP activity is decreased in a spatial as 
well as concentration dependent manner, is thought to contribute to the 
generation of signaling gradients (Ramel and Hill, 2012).  Extracellular regulation 
also occurs through heparin sulfate proteoglycans interactions that are capable 
of binding to BMPs and thereby limit their interaction with their receptors (Walsh 
et al., 2010).  These mechanisms are in place in order to generate the level or 
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gradient of BMP morphogen signaling that is required for its pleiotropic effects on 
several developmental and physiological processes.   
 
 
Gremlin 2 
Gremlin 2 (Grem2), also called Protein Related to Dan and Cerberus 
(PRDC), belongs to the DAN family of BMP antagonists together with its close 
paralog Gremlin 1 (54% identity), Dan, Dante (or Coco), Cerberus-like 1, Uterine 
sensitization-associated gene-1 (USAG-1), and Sclerostin.  The Dan family 
consists of single domain proteins that have a conserved 8-membered cystine 
ring contained within the highly conserved “Dan” domain (Avsian-Kretchmer and 
Hsueh, 2004; Nolan and Thompson, 2014; Pearce et al., 1999).   It is this Dan 
domain, a hydrophobic region at the dimer interface that binds to BMP ligands.  
In the case of Grem2, this cystine ring consists of an odd number of cysteines, 
leaving one un-paired.  Grem2 uniquely consists of 2 independent head to tail 
protein dimers, which differs from Noggin head to head dimerization (Figure 5).  
These dimers are in fact highly stable and resistant to di-sulfide bond reduction 
due to the fact that hydrogen bonding and van der Waal forces are what are 
responsible for keeping the tertiary structure of the protein together due to the 
un-paired cysteine. The N-terminus of Grem2 includes two N-linked glycosylation 
consensus sequences, as well as a flexible latch that allows for the required 
large hydrophobic interactions between antagonist-ligand.  It also works to hide 
the BMP binding epitope to prevent any non-specific binding.  Purified Grem2, 
prepared in the collaborating laboratory of Dr. Tom Thompson, was used to 
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asses its binding affinity to BMP ligands and was calculated to have an IC50 of 
less than 1nM, (Figure 6) (Kattamuri et al., 2012a, 2012b; Nolan et al., 2013).  
Grem2 was first discovered 15 years ago (Pearce et al., 1999), but its 
biological function and mechanism of BMP inhibition have remained largely 
obscure. Grem2 expression has been detected in the developing spinal cord and 
lung mesenchyme (Lu et al., 2001; Minabe-Saegusa et al., 1998), and Grem2 
has been implicated in follicle, neuronal, bone and craniofacial development 
(Ideno et al., 2009; Kriebitz et al., 2009; Sudo et al., 2004; Zuniga et al., 2011). 
Grem2 in vivo has been shown to inhibit canonical BMP signaling and in vitro 
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inhibits Bmp2 and Bmp4, but not Tgfβ or Activin (Sudo et al., 2004). Several 
DAN-family members such as Dante and Grem1 have been linked to a number 
of pathophysiological states.  Dante has been shown to promote cancer 
metastasis, and Gremlin 1 has been shown to be induced in endothelial cells 
during pulmonary arterial hypertension, in fibroblasts during idiopathic pulmonary 
fibrosis, and actually promotes Tgfβ directed epithelial to mesenchymal 
transition.  Grem1 is induced during chronic kidney disease such as diabetic 
nephropathy and is known to promote the cancer stem phenotype (Cahill et al., 
2012; Gao et al., 2012; Koli et al., 2006; Lappin et al., 2002; Owens et al., 2015).  
Although other members of the DAN family have been implicated in various 
pathological conditions, little is known about the role of Grem2 in disease. 
 
Grem2 in cardiac development and differentiation  
The Hatzopoulos laboratory recently established that during embryonic 
development in zebrafish, grem2 first appears in the ventral portion and 
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pharyngeal arch mesoderm next to the forming heart tube (Figure 7) (Müller et 
al., 2006; Muller et al., 2013). Loss- and gain-of-function approaches 
demonstrated that Grem2 is necessary for proper cardiac tube jogging and 
looping, cardiac laterality, to promote normal cardiac rhythm and cardiomyocyte 
differentiation by suppression of Smad1/5/8 phosphorylation (Figure 8) (Muller et 
al., 2013).   
Moreover, Grem2 is expressed in the cardiac field in E8 mouse embryos 
and promotes differentiation of pluripotent mouse embryonic stem (ES) cells to 
atrial-like cardiomyoctyes through activating atrial transcription factors and 
suppressing ventricular (Figure 9).  Grem2 expression begins during the 
differentiation stages of mesodermal and endodermal progenitor cells and that 
Grem2 treatment on CGR8 ES cells lead to an increase in p-JNK that was not 
seen with the treatment of other antagonists such as Noggin.  The increase in 
cardiomyoctyes via Grem2 was diminished when cells were treated with the JNK 
pathway inhibitor SP60 but not the BMP pathway inhibitor dorsomorphin.   
Therefore, Grem2-induced cardiomyocyte differentiation occurs via activation of 
the non-canonical BMP pathway JNK (Tanwar et al., 2014). 
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Summary and hypothesis  
 The cardiac tissue repair process following an acute injury such as a 
myocardial infarction is highly regulated in both a temporal and spatial dependent 
manner.  The inflammatory phase of tissue repair is a highly dynamic process 
and has been directly implicated with patient outcome and survival.  Previous 
clinical studies targeting direct players of the inflammatory process has produced 
mixed results. Taking clues from cardiac developmental processes that often get 
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re-activated during an injury response, focus has been brought to the BMP 
signaling pathway.  BMP signaling is necessary for normal cardiac 
morphogenesis to occur and is re-activated post-MI.  The level of BMP signaling 
is important for its downstream effects, and BMP antagonists are responsible for 
regulating the canonical BMP pathway.  We recently determined that a relatively 
unstudied antagonist, Grem2, is important for cardiac development, and 
therefore sought to determine if it also plays a role during the cardiac tissue 
repair process.   
According to current work conducted by the Hatzopoulos laboratory, 
Grem2 is not essential for mouse embryonic development.  However, in the adult 
heart, Grem2 is highly induced in peri-infarct cardiomyocytes at the end of the 
inflammatory phase after MI. Based on the role of BMP signaling during 
inflammation, we hypothesized that Grem2 regulates the inflammatory response 
and keep inflammation in check through suppression of canonical BMP signaling.  
We therefore investigated the role of Grem2 in the cardiac tissue repair process 
and in functional recovery.   
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CHAPTER II 
 
BMP SIGNALING AND GREM2 ARE INDUCED IN THE HEART AFTER A 
MYOCARDIAL INFARCTION 
 
 
 
Introduction 
The cardiac repair process following an acute injury such as a myocardial 
infarction consists of well-documented stages that are highly spatiotemporally 
regulated. However, the molecular pathways that regulate these processes are 
not entirely understood.  The Hatzopoulos laboratory has recently demonstrated 
that developmental pathways necessary for cardiac morphogenesis are re-
activated after injury and in fact play important roles in the recovery process 
(Aisagbonhi et al., 2011; Paik et al., 2015), and that a BMP antagonist, Grem2 is 
important for cardiac development and differentiation (Muller et al., 2013; Tanwar 
et al., 2014). BMP signaling is a pathway that has been extensively studied in the 
context of cardiac development and has been shown to be induced after 
ischemic injury in the adult mouse heart (Pachori et al., 2010; Wu et al., 2014).  
Histological analyses placed BMP signaling induction in peri-infarct 
cardiomyocytes (Chang et al., 2008).  However the exact role of BMP signaling 
and whether it is regulated after cardiac injury has not been extensively studied.   
To place BMP signaling components within the context of the MI repair 
process, we analyzed whole mouse heart RNA samples prepared at distinct time 
points after left anterior descending (LAD) artery ligation, namely at day 0 
(baseline, prior to injury), 1, 2, 3, 5, 7 and 21 after MI.  We also conducted 
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histological analysis in order to determine the localization of canonical BMP 
signaling components, namely the cell types producing both pathway 
components as well as important pathway regulators.   
 
Materials and methods 
Experimental MI 
Mice underwent open chest surgery, a 10-0 nylon suture was placed 
through the myocardium into the anterolateral left ventricular wall around the left 
anterior descending (LAD) artery and the vessel was permanently ligated 
(Aisagbonhi et al., 2011).  Male mice at 12-16 weeks of age fed with a normal 
chow diet were euthanized at defined time points following surgery to obtain 
cardiac tissue for molecular and histological analyses.   
 
RNA analysis by Reverse Transcription and quantitative Polymerase Chain 
Reaction (RT-qPCR) 
Whole hearts were dissected at the indicated time points after MI, 
perfused to remove blood cells and RNA was obtained using TriZol Reagent 
according to the manufacturer’s instruction (Life Technologies). Reverse 
transcription was conducted by incubating 100 ng of oligo(dt)15 (Promega) with 3 
µg RNA for 5 min at 70°C.  20 mM of dNTPs (GE Healthcare), 200 U/µl of Mo-
MLV reverse transcriptase with 5x associated buffer (Promega), 40 U/µl RNasin 
(Promega) and water were added to the RNA solution and incubated at 40°C for 
1 hour, followed by a 5 minute incubation at 95°C in order to inactivate enzyme 
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activity.  1:100 of the final cDNA solution or ~20 ng served as template for 
quantitative Real Time PCR with GoTaq qPCR Master Mix (Promega) using a 
C1000 Thermal Cycler (BioRad) as previously described (Aisagbonhi et al., 
2011).  0.5 µM of Gapdh primers were included as an internal control and relative 
gene induction levels were determined using the 2(–DDCt) formula (Beck et al., 
2008; Livak and Schmittgen, 2001).  Experiments were done in triplicates.  The 
sequences of gene-specific primers have been included in Table 1.  
 
Immunofluorescence and immunohistochemistry analyses  
For IF on cardiac tissue sections, freshly isolated hearts were perfused 
with 1X Phosphate Buffered Saline (PBS), bisected transversely, embedded in 
Optimal Cutting Temperature (OCT) compound, frozen on dry ice, cut into 10 µm 
thick sections and stored at -70oC until use.  Before antibody staining, slides 
were thawed at room temperature, immersed in cold 1:1 acetone: methanol and 
fixed for 5 minutes on ice.  Slides with cardiac tissue sections were washed three 
times in 1X PBS for 5 minutes each wash, and incubated with blocking buffer 
containing 1% bovine serum albumin (BSA) and 0.05% saponin in 1X PBS for 1 
hour at room temperature.  Next, sections were stained with primary antibodies 
overnight at 4°C in blocking buffer.  Afterwards, slides were washed five times in 
1X PBS for 5 minutes each, incubated with secondary antibodies and DAPI for 1 
hour at room temperature in blocking buffer, washed in 1X PBS three times for 5 
minutes each, and mounted with VECTASHIELD fluorescent mounting medium 
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(Vector Laboratories). The Vanderbilt Histology Core provided histological 
services, including tissue sectioning.   
Primary antibodies used for IF analysis were as follows: rat monoclonal 
anti-mouse CD31/PECAM1 (BD Pharmingen; 1:100, Cat. No. 553370), rabbit 
monoclonal anti-mouse p-Smad1/5/8 (Cell Signaling; 1:50, Cat. No. 9511), 
mouse monoclonal anti-mouse MF20 (Developmental Studies Hybridoma Bank; 
1:5, Cat. No. MF 20, RRID:AB_2147781), rabbit polyclonal anti-human Grem2 
(GeneTex; 1:100, Cat. No. GTX108414), rabbit monoclonal Id2 (Biocheck Can. 
No. BCH-3/#9-2-8), and mouse monoclonal α-Actinin (Sigma; 1:800, Cat. No. 
A7811).  Secondary antibodies used for IF were: goat anti-mouse Cy3-
conjugated (Cat. No. 115-165-146), goat anti-rat Cy3 (Jackson 
ImmunoResearch, Cat. No. 712-165-150), and goat anti-rabbit Alexa-Fluor-488-
conjugated (Life Technologies, Cat. No. A21206).  Cy3 antibodies were used at a 
1:200 dilution and Alexa-Fluor-488 was used at a 1:400 dilution.  Cardiac tissue 
sections were stained with the fluorescent dye 4’,6-diamidino-2-phenylindole 
(DAPI, 1:5000 dilution; Invitrogen) to mark cellular nuclei.  Images were taken on 
the Olympus FV-1000 inverted confocal microscope and processed using the 
FV10-ASW 1.6 Viewer software (Olympus).   
p-Smad1/5/8+ cardiomyocytes were quantified using ImageJ 1.46r (NIH) 
color thresholding, as a percentage of cells double positive for MF20 and p-
Smad1/5/8 amongst all DAPI positive cells in the viewing field; at least 4 viewing 
fields were used for calculations.   
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The human heart tissue samples were obtained from Vanderbilt 
Cardiology Main Heart Registry/Biorepository. The study was approved by 
Vanderbilt Institutional Review Board and written informed consent was obtained 
from all heart tissue donors or organ donor families. Explanted heart from 
patients with ischemic cardiomyopathy or organ donors whose heart were 
unmatched for transplantation was collected into the Biorepository. At the time of 
explantation, a section of left ventricular (LV) free wall tissue was immediately 
frozen in liquid nitrogen, and a small piece of LV tissue from the same section 
was embedded in OCT media and stored at -80oC until used for 
immunofluorescence analysis.  
 
Statistical Analysis 
Statistical analysis was performed using GraphPad Prism software.  Data 
are represented as the mean ± SEM.  Student’s two-tailed unpaired t-test was 
used for comparison between two groups, one-way ANOVA was used to 
compare multiple groups, and two-way ANOVA was used to compare gene 
induction in each mouse model over time.  Dunnett’s and Bonferroni’s multiple 
comparisons test was used post-hoc.  *P<0.05, **P<0.01, ***P< 0.001, 
****P<0.0001 were considered significant.  
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Results 
Dynamic induction patterns exist for members of the inflammatory and fibrotic 
pathways 
Using qPCR, with typical inflammatory gene markers, such as Il-1β and E-
selectin, and markers of granulation tissue formation and fibrosis, such as Tgfβ1 
and alpha Smooth Muscle Actin (αSma), we determined that pro-inflammatory 
genes are induced early and peak at days 1-2 after MI, whereas fibrosis genes 
are induced at day 5, as expected (Frangogiannis, 2014; Paik et al., 2015; Virag 
and Murry, 2003).  Gene induction of inflammatory genes returned to baseline 
levels between days 3 to 5, whereas Tgfβ1 expression returned to baseline at 
day 21.  αSma levels declined, but were still detectable at day 21, reflecting the 
presence of myofibroblasts during the scar maturation phase (Figure 10A).  
 
Dynamic changes in the expression of BMP pathway components and their 
antagonists occur after a myocardial infarction 
Investigation of BMP ligands after MI showed that Bmp2 is the earliest 
induced ligand of the BMP family at day 1 with its expression peaking at day 3, a 
pattern that corresponds to the inflammatory stage of cardiac repair.  Previous 
work documented Bmp2 protein induction occurs primarily in peri-infarct area 
cardiomyocytes and not in recruited immune cells (Chang et al., 2008).  Bmp2 is 
subsequently downregulated to pre-injury levels by day 7 after MI.  Bmp2 
suppression coincides with up-regulation of Bmp4, Bmp6, and Bmp10, the 
expression of which starts around day 5 and persists during fibrosis and scar 
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formation (Figure 10B).   Consistent with the induction of distinct BMP ligands 
during different stages after MI, there was an overlapping expression of the only 
BMP signaling target gene that showed a significant induction post-MI throughout 
	  	  31	  
the repair process, Id2 (Figure 11A).  BMP receptor induction illustrated that 
BmpR2 was the only receptor with a significant induction (Figure 11C).  In 
contrast, analysis of BMP signaling antagonists showed minimal changes in their 
expression levels after MI with the notable exception of Grem2 that is induced at 
day 2, peaks at day 5 after MI and returns to pre-injury levels at day 21 (Figure 
10C, with absolute expression values after GAPDH normalization in Figure11B). 
The Grem2 induction pattern follows the pattern of Bmp2 with one-day delay.   
We did not detect a signal for its close paralog Grem1 at baseline, or at the 
tested time points after MI (Figure 11B).  Although Grem2 is the most 
prominently induced BMP antagonist after MI, absolute expression values 
indicate that during homeostasis the heart maintains expression of Dan, Sost, 
Twsg1 and Chordin which, however are at least 40 (Chordin) to 400 (Dan, 
Twsg1) times less potent BMP inhibitors than Grem2, or do not bind directly to 
BMP ligands (Sost) (Figure 11B; Nolan et al., 2015; Zhang et al., 2008).  
Consistent with the Bmp2 induction pattern after MI, immunofluorescence 
(IF) analysis at day 2 post-MI, using antibodies recognizing the phosphorylated, 
i.e., activated form of Smad1/5/8, demonstrated activation of canonical BMP 
signaling in endothelial cells in the peri-infarct area and cardiomyocytes at the 
border zone of the infarcted tissue.  In contrast, we did not detect active 
Smad1/5/8 within ventricular tissue prior to injury (Figure 10D).   
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BMP pathway components are expressed in the border zone and infarct areas 
post-MI 
 Immunofluorescence analysis indicated that BMP pathway components 
are expressed at higher levels in the border zone and infarct area compared to 
distal or uninjured tissue areas.  IF staining with antibodies recognizing the 
phosphorylated, i.e., active form of Smad1/5/8, showed that canonical BMP 
signaling is active in peri-infarct cardiomyocytes of WT mice in agreement with 
previous reports showing that BMP ligands are expressed in this region and not 
present in cardiomyoctyes distal to the infarct (Chang et al., 2008).   (Figure 12A 
and B). Id2 expression is mainly localized within the infarct, likely in inflammatory 
cells (Figure 12C).  
Antibody staining revealed that the robust induction of Grem2 protein 
expression after MI takes place primarily in peri-infarct cardiomyocytes with no 
Grem2 detected in distal areas away from the infarct (Figure 12D). In the case of 
human patients, very little Grem2 is expressed within the heart tissue of healthy 
patients, however Grem2 is expressed within the cardiomyocytes of ischemic 
cardiomyopathy patients (Figure 12E). 
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Discussion 
In conclusion, our data indicate a bi-phasic pattern of BMP ligand 
induction after MI, i.e., early upregulation of Bmp2 expression during the 
inflammatory stage, followed by a second phase during granulation tissue and 
scar formation that is dominated by several ligands, including Bmp4, Bmp6, and 
Bmp10.   Conversely, Grem2 is the prominent BMP antagonist induced after MI 
with its expression starting at day 2, peaking during the transition from 
inflammation to granulation tissue formation, and returning to baseline levels 
during scar formation.  BMP pathway components are being induced in the 
infarct or border zone areas, with Grem2 being produced by cardiomyocytes in 
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both the mouse model of acute MI as well as human ischemic cardiomyopathy 
patients.   
 The cellular response following a myocardial infarction has been well 
described, but the molecular pathways responsible for regulating each phase of 
the response is not entirely understood (Boudoulas and Hatzopoulos, 2009).  Our 
data indicate that BMP signaling is involved in the cardiac repair process after 
MI, as has been previously reported (Chang et al., 2008; Pachori et al., 2010; Wu 
et al., 2014).  However, to our knowledge, ours is the first study to show that 
canonical BMP signaling activation after MI coincides with the induction of 
inflammatory process genes.  We are also the first group to investigate the roles 
of endogenous antagonists in the cardiac repair process. Specifically, we show 
that the BMP antagonist Grem2 is robustly and transiently induced after 
myocardial infarction during the late inflammatory phase and early proliferative 
phase of granulation tissue formation.  Grem2 protein is synthesized primarily in 
peri-infarct cardiomyocytes, a domain that overlaps both with the expression of 
Bmp2 after MI and the area of p-Smad1/5/8, i.e., canonical BMP signaling 
activation.  Some p-Smad1/5/8 persists in cardiomyocytes, even with Grem2 
induction, which may be due to the presence of ligands such as GDFs or Activins 
that can induce Smad1/5/8 phosphorylation, but are not inhibited by Grem2 
(Sudo et al., 2004).  Persistent activity suggests that additional canonical BMP 
signaling inhibition may be required after MI to supplement Grem2. Previous 
reports have linked activation of BMP signaling to cardiomyocyte apoptosis 
(Pachori et al., 2010) during the early stages of ischemia/reperfusion injury, as 
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well as fibrosis and hypertrophy (Sun et al., 2013), so Grem2 may also have 
direct cardioprotective properties. 
However, the question remains if the timing of BMP pathway induction 
directly correlates with the regulation of the inflammatory process following a 
myocardial infarction.  In order to test if this is a case, mouse models that are 
engineered to have changes in the expression of BMP pathway components 
could be challenged with an MI.  Since Bmp2 is the ligand induced during the 
inflammatory phase, a conditional cardiac cell specific knockout mouse could be 
used to test if its presence is necessary for the inflammatory phase to occur, or if 
lack of Bmp2 alters the inflammatory response in any way.  This would lead to 
determining whether BMP signaling regulates the inflammatory response, but 
would not lead to directly determining a therapeutic target.  Since our data also 
demonstrate that the relatively unstudied protein, Grem2 is the only endogenous 
antagonist induced at the end of the inflammatory response, it would therefore be 
valuable to investigate if Grem2 is necessary to regulate the inflammatory 
response post-MI.  These investigations are the topics of the following chapters.  
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CHAPTER III 
 
LOSS OF GREM2 LEADS TO AN INCREASE IN THE MAGNITUDE OF 
INFLAMAMTION, THEREBY WORSENING CARDIAC FUNCTION POST-MI 
 
 
Introduction 
The inflammatory phase following a myocardial infarction is a highly 
dynamic process that exerts pleiotropic effects on the subsequent stages of the 
cardiac repair process.    The purpose of inflammation in this context is to clear 
the cellular debris present after the loss of blood flow that leads to massive cell 
death.  However the inflammatory response that gets activated after acute injury 
may be more severe (i.e. prolonged) than is necessary.  As a result, excessive 
inflammation leads to an increase in cell death and in the fibrotic response; all 
together leading to the injury into what was previously healthy tissue 
(Frangogiannis, 2014).  
Excessive inflammation has been linked to worse outcomes after a 
myocardial infarction in both animal models and in human patients.  Therefore 
several clinical trials have been attempted in order to limit this inflammatory 
response.  However so far these trials have been largely unsuccessful since they 
have directly targeted components of the inflammatory response, a process that 
is necessary for cardiac repair to occur (Christia and Frangogiannis, 2013).    
BMP signaling has been implicated in promoting inflammation as well as 
induced by pro-inflammatory mediators in other disease states such as 
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atherosclerosis and anemia (referenced in CHAPTER I).  Our data also indicate 
that BMP signaling is activated during the inflammatory phase of cardiac 
recovery post-MI and is followed by the induction of the pathway antagonist 
Grem2.  Therefore we hypothesized that pro-inflammatory mediators increase 
the inflammatory response in both magnitude and duration by activating the BMP 
pathway post-MI, and that Grem2 is necessary to limit and terminate this 
inflammatory response.   
 
Materials and methods 
 Generation of genetically engineered Grem2 mice 
In order to inactivate the Grem2 gene and generate Grem2-/- mice, Dr. 
John Schoenhard and Amrita Mukerjee in our laboratory first constructed an 
insertion vector (kindly provided by Dr. Mark Magnuson) containing two 
fragments from the Grem2 gene locus (fragments B and C, each 0.5 kb in length) 
flanking a kanamycin selection gene cassette under the synthetic EM7 
prokaryotic promoter (EM7neo) and a fusion puromycin/truncated herpes simplex 
virus thymidine kinase gene [pu(Δ)TK; Figure 13A)]. Fragment B is located 
within the Grem2 single intron just upstream of exon 2, which contains the entire 
Grem2 coding sequence.  Fragment C resides within the 3’ UTR.  The truncated 
thymidine kinase was incorporated to facilitate clone selection in future 
recombination strategies. Homologous recombination between a BAC containing 
the WT Grem2 locus and the insertion vector replaced the entire coding 
sequence and part of the 3’ UTR of the Grem2 gene with the pu(Δ)TK/EM7neo 
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cassette.  A vector containing two additional small fragments of the Grem2 gene 
locus (Fragments A and D), also 0.5 kb in length, were used to retrieve the 
resultant targeting vector from the modified BAC (Figure 13A). 
200 g of the targeting vector were linearized and double-electroporated 
into 3.5 x 107 129/Sv mouse embryonic stem cells at the Vanderbilt Transgenic 
Mouse/Embryonic Stem Cell Shared Resource (TMESCSR).  After puromycin 
selection at 1.5 g/ml, 483 colonies were picked and 25 colonies were identified 
as having properly recombined by Southern blotting using 5’ and 3’ probes 
outside the targeting vector (the location of the probes are marked in Figure 
13A).  The targeting efficiency was 5.2%.  Six positive clones were subsequently 
expanded and confirmed by secondary screening.  Two selected clones were 
then injected into C57BL/6 blastocysts and blastocysts were transplanted into 
pseudopregnant females.  Both clones gave germline transmission generating 
two independent Grem2-/- mouse lines that displayed identical physiological 
phenotypes and response to myocardial ischemic injury.  The Grem2-/- mice and 
littermate WT controls (WTmix) were kept on a mixed C57BL/6 and 129/Sv 
background.   
Histological, molecular and flow cytometric analyses were conducted 
using male mice at 12-16 weeks of age fed with a normal chow diet.  
 
Experimental MI 
See CHAPTER II. 
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Echocardiography 
Mice underwent echocardiography measurements in order to assess 
cardiac function post-surgery.  Mice were rested and calmed before 
echocardiography was performed. All mice were conscious and unsedated 
during imaging using the VEVO 2100 machine and transducer MS-400 
(VisualSonics) to measure and calculate cardiac parameters.  The left ventricle 
was located in B-Mode and was traced over five consecutive beats in M-Mode.  
Left ventricular internal dimension and volume in diastole and systole (LVIDd, 
LVIDs, LVvold, LVvols) were measured from M-Mode using the short axis and 
used to calculate fractional shortening and ejection fraction (Paik et al., 2015).  
  
RNA analysis by Reverse Transcription and quantitative Polymerase Chain 
Reaction (RT-qPCR) 
 See CHAPTER II.  The sequences of gene-specific primers used in this 
chapter have been also included in Table 1. 
 
Immunofluorescence and immunohistochemistry analyses 
See CHAPTER II. 
Primary antibodies used for IF analysis were as follows: rabbit polyclonal 
anti-human Tie1 (Santa Cruz Biotechnology, 1:100, Cat. No. sc-342 (C-18), rat 
monoclonal anti-mouse CD31/PECAM1 (BD Pharmingen; 1:100, Cat. No. 
553370), Cat. No. MF 20, RRID:AB_2147781), rabbit polyclonal anti-human 
Grem2 (GeneTex; 1:100, Cat. No. GTX108414), rat monoclonal anti-mouse 
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CD62E/E-selectin (BD Pharmingen; 1:100, Cat. No. 550290), rat monoclonal 
anti-mouse CD45 (BD Pharmingen; 1:100, Cat. No. 550539), and mouse 
monoclonal -Actinin (Sigma; 1:800, Cat. No. A7811).  
 
Flow Cytometry 
Together with Dr. Mohamed Saleh in Dr. David Harrison’s laboratory, we 
prepared single cell suspensions of cardiac cells depleted of cardiomyocytes 
from freshly isolated whole hearts perfused with 1X PBS to remove blood cells.  
Briefly, hearts were digested with Collagenase D (2 mg/ml; Roche) and DNase I 
(100 µg/ml) in a solution of RPMI 1640 (Gibco) containing 10% FBS using an 
AUTOMacs Dissociator (Miltenyi Biotech), and then incubated at 37°C for 30 
minutes in an orbital shaker to prepare single cell suspensions.  The digested 
tissue was then passed through a 70-micron cell strainer and centrifuged at 500 
g for 10 minutes.  The cell pellet was suspended in 2 ml 1X PBS and centrifuged 
at 300 g for 5 minutes. Two more centrifugation/wash steps followed, and the 
pellet was suspended in 100 µl of FACS buffer (1% BSA, 0.5% NaN3 in 1X PBS).  
We then added 2 µl of Fc blocker (eBioscience) and cells were incubated for 10 
minutes at 4°C to prevent non-specific antibody binding, then washed with 1 ml 
of FACS buffer and centrifuged at 300 g for 5 minutes.  The cells were 
resuspended in 100 µl of FACS buffer and antibodies were added at 1 µl or 0.25 
µg per 1 million cells and incubated for 30 minutes at 4°C.  The antibodies used 
were Brilliant Violet 510–conjugated (BV510) anti-CD45 antibody (Biolegend, 
Cat. No. 103107), Alexa Fluor 488–conjugated anti-F4/80 antibody (Biolegend, 
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Cat. No. 123119), PE-Cy7-conjugated anti-Ly6C (eBioscience, Cat. No. 25-5932-
80), Brilliant Violet 421-conjugated anti-CCR2 (Biolegend, Cat. No. 150605), PE-
conjugated anti-Ly6G (Biolegend, Cat. No. 127607), and APC-Cy7-conjugated 
anti-CD3 (BD Pharmingen, Cat. No. 557596).   
After incubation, cells were centrifuged at 300 g for 5 minutes and washed 
twice with 1ml FACS buffer.  5 µl of 7-AAD (eBioscience) was added to 100 µl of 
the solution and incubated for 10 minutes at room temperature for live/dead 
staining.   After 300 µl of FACS staining buffer was added, cells samples were 
analyzed by flow cytometry using the BD FACSCanto II cytometer.  Total cell 
number was determined by adding 50 µl of counting beads (~49500-52000 
beads per µl; Life Technologies).  Flow-minus-one was used for gating. Low 
voltage gating was conducted in order to capture the counting bead population. 
All leukocyte populations were quantified within the CD45+ gate.  Data acquisition 
was completed using FloView.   
Regarding total blood flow sorting, 100 µl of fresh heparinized blood was 
directly stained with 1.5 µl of each of the previously mentioned antibodies for 30 
minutes at 4°C.  The samples were then washed with FACS buffer. 2ml of red 
blood cell lysis buffer was applied per 100µl of blood for 4 minutes at room 
temperature. Two additional rounds of washing and centrifugation at 1500g for 3 
minutes followed.  7-AAD staining was conducted as described for the heart 
samples.   
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TTC Staining 
 Whole mouse hearts were isolated 24 hours post-MI, flash frozen, and 
then cut into 1mm sections as instructed by Dr. Rich Gumina.  The sections were 
incubated in 1.5% TTC at 37°C for 30 minutes and then fixed in 10% formalin 
overnight, and finally imaged. ImageJ 1.46r (NIH) was used to outline infarct 
(white) tissue. Infarct size is reported as a percentage of the total left ventricular 
(LV) area.   
 
 
Statistical Analysis 
Statistical analysis was performed using GraphPad Prism software.  Data 
are represented as the mean ± SEM.  Student’s two-tailed unpaired t-test was 
used for comparison between two groups, one-way ANOVA was used to 
compare multiple groups, and two-way ANOVA was used to compare gene 
induction in each mouse model over time.  Dunnett’s and Bonferroni’s multiple 
comparisons test was used post-hoc. *P<0.05, **P<0.01, ***P< 0.001, 
****P<0.0001 were considered significant.  
 
Results 
Loss of Grem2 leads to an increase of endothelial pro-inflammatory markers after 
MI  
To determine whether Grem2 has a role in cardiac repair, we generated a 
loss of function (Grem2-/-) mouse model by deleting most of exon 2 via 
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homologous recombination  (Figure 13A; Figure 14A-C; see also Methods).  
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This approach deleted the entire coding sequence and most of the 3’ 
untranslated region of the Grem2 gene, leading to complete loss of Grem2 
protein. Grem2-/- mice are viable without major structural or physiological defects 
or apparent differences in heart size, cardiac tissue morphology and cardiac 
function as compared to WT siblings, with the exception of a small increase in 
heart rate (Table 2; Figure 14D,E).  Thus, although the Grem2 expression 
pattern has been conserved in zebrafish and mouse embryos, where Grem2 is 
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first expressed in the area of the secondary heart field (Muller et al., 2013; 
Tanwar et al., 2014), Grem2 appears to be dispensable for mouse development.  
Antibody staining revealed that the robust induction of Grem2 protein expression 
after MI takes place primarily in peri-infarct cardiomyocytes (Figure 13B).  There 
was no Grem2 detected in distal areas away from the infarct (data not shown).  
There was also a complete absence of Grem2 protein in Grem2-/- mice, further 
corroborating their null phenotype (Figure 13B). 
In order to test whether the sequential induction of Bmp2 and Grem2 
during the inflammatory phase plays a role in inflammation after acute injury, we 
challenged Grem2-/- and WT sibling mice with experimental MI by permanent 
ligation of the LAD coronary artery.  We then isolated whole heart RNA at day 0, 
2, 7 and 21 after MI and analyzed the expression of pro-inflammatory genes.   
Our data show that induction of genes encoding endothelial cell membrane 
proteins implicated in the rolling and adhesion of circulating immune cells to the 
vascular wall are higher in Grem2-/- hearts compared to WTs. Specifically, RNA 
analysis showed that expression of E-selectin, Vcam1, and Icam1 are further 
upregulated compared to WT controls at day 2 and 7 after MI; however, their 
expression decreases at day 21 to levels comparable to WT hearts (Figure 13C).  
Consistent with the gene induction results, IF analysis of cardiac tissue sections 
at day 7 after MI revealed that endothelial cells (Tie1) within the infarct and peri-
infarct areas stain positively for E-selectin protein in Grem2-/- mice, whereas, at 
this stage, E-selectin is almost undetectable in WT controls (Figure 13D). 
Comparison of chemokine expression such as Ccl2, Il-8, and Il-1β showed, that 
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although chemokines are induced after MI as expected, relative expression 
levels were comparable between Grem2-/- and WT mice, except a further 1.7-fold 
increase of Ccl2 expression in Grem2-/- mice compared to WT  (Figure 15).  
Thus, our data show that lack of Grem2 enhances the pro-inflammatory 
phenotype of endothelial cells in and around the injury site after MI.   
 
Loss of Grem2 leads to an increase in the magnitude of inflammation and spread 
of inflammation 
To test whether increased expression of pro-inflammatory makers after MI 
augments infiltration of immune cells, we isolated hearts at day 5 after MI and 
analyzed histological sections with an antibody recognizing the leukocyte marker, 
CD45.  The results showed that infiltration of CD45+ cells after MI appeared more 
abundant in Grem2-/- hearts compared to WT (Figure 16A).  To quantify the 
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increase in inflammatory infiltrate and better characterize the corresponding cells, 
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we prepared single cell suspensions of non-cardiomyocyte cells and conducted 
flow cytometry using antibodies recognizing various immune cell markers such 
as CD45, Ly6C, Ly6G, CD3, F4/80, and Ccr2 (Nahrendorf et al., 2007; Yan et al., 
2013; Hulsman et al 2016).  As shown in Figure 16B, there was a 3-fold increase 
in the inflammatory cells, identified as CD45+ cells, in Grem2-/- hearts after MI as 
compared to WTs.  Within the CD45+ population, there was a 2-3-fold increase in 
Ly6Chi cells that represent mostly monocytes (but may also include neutrophils 
and T-cells that express intermediate levels of Ly6C), neutrophils (Ly6G+), T-cell 
lymphocytes (CD3+), and macrophages (F4/80+).  There was a similar increase in 
Grem2-/- hearts compared to WTs of pro-inflammatory F4/80+ macrophages 
expressing high levels Ly6C (F4/80+/Ly6Chi), the Monocyte chemoattractant 
protein-1 (MCP-1, or Ccl2) receptor Ccr2 (F4/80+/Ccr2hi), or both 
(F4/80+/Ly6Chi/Ccr2hi).  The gating strategy and representative flow cytometry 
plots are shown in Figures 17 and 18.  
Analysis of the initial necrosis area using Triphenyl tetrazolium chloride 
(TTC) staining 1 day after MI showed that infarct sizes were comparable between 
WT and Grem2-/- mice, suggesting that the observed differences in the 
inflammatory response are not due to more severe infarcts in Grem2-/- mice 
(Figure 19).  Furthermore, flow cytometry analysis on blood CD45+ cells isolated 
from Grem2-/- and WT mice at baseline and 5 days after MI revealed that 
leukocyte numbers in the blood were not significantly different at baseline.  After 
MI, circulating leukocyte numbers were increased as expected (Swirski et al., 
2009), albeit numbers were ~2 times higher in Grem2-/- mice, likely because 
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circulating leukocyte numbers correlate with the magnitude of the inflammatory 
response (Figure 20; Chia et al., 2009).   
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Finally, we investigated whether loss of Grem2, besides increased 
inflammatory cell infiltration, also leads to prolonged inflammation.  To this end, 
we quantified inflammatory cells by flow cytometry at day 14 after MI, a time point 
when inflammatory cell numbers return close to baseline levels in WT mice.  Our 
results showed a dramatic drop in inflammatory cells in Grem2-/- mice to levels 
comparable to WT controls (Figure 16C), consistent with the eventual 
downregulation of cell adhesion molecules in Grem2-/- hearts after MI (Figure 
16D).  Specifically, CD45+ cell numbers in Grem2-/- decreased 40-fold from day 5 
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to 14, Ly6C+ cells 80-fold, and F4/80+ cells 10-fold (Figure 16A,C).  Furthermore, 
molecular analysis indicated an increase in the induction of genes encoding 
proteins involved in the resolution of inflammation such as Tgfβ1 and Il-10 in 
Grem2-/- mice compared to WT animals, which may account for the clearing of 
excessive inflammatory cells in Grem2-/- cardiac tissue (Figure 16D).  Taken 
together, our results indicate Grem2 is necessary to regulate the magnitude, but 
not the duration of the inflammatory cell infiltration after MI. 
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Loss of Grem2 leads to worse cardiac function post-MI 
Excessive inflammation has been linked to poor prognosis after MI both in 
animal models and human patients (Lefer et al., 1993; Simpson et al., 1988; 
Anzai et al., 1997; Gonzalez-Quesada and Frangogiannis, 2009; de Lemos et al., 
2007; Christia and Frangogiannis, 2013).  To determine the effects of Grem2 
loss-of-function on cardiac recovery, we compared cardiac functional parameters 
among WT controls and Grem2-/- mice by M-mode echocardiography at various 
time points after MI (Figure 21).  Grem2-/- mice have worse cardiac function 
compared to their corresponding WT siblings of mixed C57BL/6 and 129/Sv 
background (WTmix) as evidenced by higher fractional shortening (FS) and 
ejection fraction (EF) values 21 days after MI (Figure 21A).   Specifically, systolic 
diameters were higher in Grem2-/- mice compared to WTmix controls, 
demonstrating that the changes to cardiac function are likely due to the changes 
in the magnitude of inflammation, since systolic dysfunction is often linked to 
these phenotypes (Figure 21B; (Frangogiannis, 2014; Saxena et al., 2015). 
Grem2-/- mice have comparable ventricular dimensions and functional values to 
corresponding WT control mice at baseline (Figure 21B).  These data indicate 
that Grem2 levels directly correlate with functional recovery after acute MI.  
Original M-mode echocardiography images are shown in Figure 21C.   
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Discussion 
 The mechanisms responsible for inducing the inflammatory response after 
MI have been well described, but those that regulate the magnitude or spread of 
inflammatory cells are less well understood (Frangogiannis, 2014).  Our results 
suggest that Grem2 controls the magnitude but not the duration of the 
inflammatory response, likely due to the fact that lack of Grem2 also triggers 
overexpression of cytokines and growth factors involved in the resolution of 
inflammation such as Tgf1 and Il-10.  The effects of Grem2 loss in increasing the 
inflammatory response correlate with ventricular function after MI, as evidenced 
by deteriorated systolic parameters in Grem2-/- mice as compared to WT 
littermate controls. This represents the first time Grem2 has been implicated in 
the adult cardiac repair program and in the regulation of a disease state such as 
inflammation.     
The Hatzopoulos laboratory has previously shown that Grem2 is 
necessary for cardiac asymmetry and atrial development in zebrafish.  However, 
it appears that Grem2 is dispensable for mouse development.  This result is not 
without precedent among BMP signaling components.  For example, single 
Bmp5, Bmp6, and Bmp7 knockout mice are viable, but double knockouts of 
either Bmp5/7 or Bmp6/7 are embryonic lethal due to cardiac developmental 
defects (Kingsley et al., 1992; Dudley et al., 1997; Kim et al., 2001; Solloway et 
al.,1998; Solloway et al., 1999). It is likely that, as with Bmp ligands, there is 
redundancy among BMP antagonists in cardiac development. Such redundancy 
may also happen in the adult heart.  
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Although Grem2 is the highest induced BMP antagonist induced after MI, 
the heart maintains expression of a number of BMP antagonists such as Chordin, 
Sost, Twsg1 and Dan.  There are also low levels of Noggin expression.  Sost 
does not inhibit BMP2 and thus is unlikely to play a role in the inflammatory 
response, which is dominated by BMP2 expression.  Dan, Chordin and Twsg1 
are weaker antagonists than Grem2 and may not compensate for Grem2 in the 
peri-infarct area where Grem2 is prominently induced (Nolan et al., 2015; Zhang 
et al., 2008). It would be informative to generate double loss of function mice by 
crossing the Grem2-/- mice to mice with conditional inactivation of other BMP 
antagonists such as Grem1 or Noggin to directly test redundant functions during 
development or after injury. 
Again, due to the global, constitutive nature of our knockout model, the 
possibility remains that some of the phenotypic effects observed could be caused 
by the system compensating for the lack of Grem2.   This could be examined by 
removing the expression of Grem2 only during the inflammatory phase of 
recovery by utilizing a conditional knockout model.  If the loss of Grem2 during 
the inflammatory response results in an increase in the magnitude of 
inflammation, then it is unlikely that other mechanisms are directly involved.   
 Although our findings suggest that Grem2 is necessary to control the 
magnitude of inflammation, it does not demonstrate whether it is sufficient.  In 
order to determine if additional Grem2 has a beneficial effect on inflammation 
and the cardiac repair process, a gain of Grem2 function animal model should be 
utilized to determine if the inflammatory response is augmented, and if more 
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importantly, this leads to positive effects on cardiac functional recovery.  The 
Hatzopoulos laboratory has generated a transgenic model of Grem2 
overexpression, and the results of these studies are the topic of the subsequent 
chapter.   
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CHAPTER IV 
 
 
 
GAIN OF GREM2 FUNCTION LEADS TO A DECREASE IN THE MAGNITUDE 
OF INFLAMMATION AND AN IMPROVEMENT IN CARDIAC FUNCTION 
 
 
Introduction 
 BMP signaling antagonists have been implicated in the regulation of the 
inflammatory phenotype present in vascular disease states, such as 
atherosclerosis. Endogenous inhibitors such as Noggin, BMPER, and Grem1 and 
chemical inhibitors such as dorsomorphin have previously been demonstrated to 
inhibit the pro-inflammatory effect of BMP signaling on endothelial cells (Chen et 
al., 2004; Helbing et al., 2011; Pi et al., 2012; Simões Sato et al., 2014; 
Steinbicker et al., 2011; Sucosky et al., 2009).  Despite the fact that such 
antagonists have extensively been studied in the context of disease, a relatively 
unstudied Bmp antagonist is Grem2, has not previously been implicated in 
disease states, with exception of atrial fibrillation (Tanwar et al., 2014).   
In addition to inflammation, BMP antagonism has also been shown to 
exert beneficial effects on the cardiac repair process (Pachori et al., 2010; Sun et 
al., 2013).  Since the data described in the previous chapter illustrated that 
Grem2 is necessary for the regulation of the magnitude inflammation, as 
evidenced by a Grem2 loss-of-function model, I wanted to determine if Grem2 
was also sufficient for the regulation of the inflammatory process following an MI.  
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In order to test this, the Hatzopoulos laboratory generated a transgenic (TG) 
gain-of-function model for Grem2.  
 
Materials and methods 
Generation of genetically engineered Grem2 mice 
The MHC-Grem2 plasmid was generated by inserting the full-length 
Grem2 cDNA into the αMHC (Myh6) gene promoter-polyA hGH cloning vector 1 
(kindly provided by Dr. J. Robbins; (Subramaniam et al., 1991)).  The αMHC-
Grem2 transgenic (TGGrem2) mice were generated by pronuclear microinjection of 
the construct into fertilized oocytes at the TMESCSR.  TGGrem2 mice and WT 
littermate controls were raised in C57BL/6 background.   
Histological, molecular and flow cytometric analyses were conducted 
using male mice at 12-16 weeks of age fed with a normal chow diet.  
 
Experimental MI and Grem2 administration 
See CHAPTER II. 
Grem2 protein for mouse administration was provided by the laboratory of 
Dr. Thomas Thompson at the University of Cincinnati and was synthesized, 
purified and measured activity as previously described (Kattamuri et al., 2012a; 
Nolan et al., 2013).  WT mice were injected with 1 µg Grem2 protein per gram of 
body weight or vehicle (sterile 1X PBS) via intraperitoneal injection (IP) once per 
day at day 2, 3, and 4 following MI.   
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Echocardiography 
See CHAPTER III. 
  
RNA analysis by Reverse Transcription and quantitative Polymerase Chain 
Reaction (RT-qPCR) 
See CHAPTER II.  The sequences of gene-specific primers for this 
chapter have also been included in Table 1.  
 
Flow Cytometry 
See CHAPTER III. 
 
Statistical Analysis 
Statistical analysis was performed using GraphPad Prism software.  Data 
are represented as the mean ± SEM.  Student’s two-tailed unpaired t-test was 
used for comparison between two groups, one-way ANOVA was used to 
compare multiple groups, and two-way ANOVA was used to compare gene 
induction in each mouse model over time.  Dunnett’s and Bonferroni’s multiple 
comparisons test was used post-hoc. *P<0.05, **P<0.01, ***P< 0.001, 
****P<0.0001 were considered significant.  
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Results 
Grem2 overexpression attenuates the inflammatory response after MI 
To explore the possibility that Grem2 controls the extent of inflammation 
after MI, we generated a transgenic mouse line where Grem2 is postnatally 
overexpressed in adult cardiomyocytes under the control of regulatory elements 
from the alpha-myosin heavy chain (MHC or Myh 6) promoter that are active in 
the adult heart (TGGrem2; Figure 22A; Figure 23; see also Methods).  TGGrem2 
mice did not exhibit differences in cardiac morphology and function as compared 
to WT counterparts (Table 3; Figure 23). 
TGGrem2 and WT siblings underwent permanent LAD ligation and whole 
heart RNA was isolated at day 0, 1, 2, 3, 5, and 7 after MI.  qPCR analysis 
showed that gain-of-Grem2-function led to a significant reduction in the induction 
levels of inflammatory gene markers such as E-selectin and Vcam1 after MI with 
no changes in the induction of pro-inflammatory cytokines (Figure 22B, Figure 
16).  Flow cytometry of cardiac cells 5 days after MI, excluding cardiomyocytes, 
confirmed that reduced expression of pro-inflammatory markers led to a 
significant decrease in the number of CD45+leukocytes, Ly6C+ monocytes, and 
F4/80+ macrophages within cardiac tissue (Figure 22C; original flow graphs are 
shown in Figure 24). Attenuation of inflammation correlated with reduced 
induction of genes encoding the anti-inflammatory Il-10 cytokine and Tgf1 
(Figure 22D).  These data indicate Grem2 overexpression is able to contain the 
magnitude of the inflammatory response after MI.  
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Grem2 promotes functional recovery after MI 
The phenotypic analysis of TGGrem2 mice indicates that Grem2 levels are 
inversely related to the magnitude of inflammation after MI.  Excessive 
inflammation has been linked to poor prognosis after MI both in animal models 
and human patients (Lefer et al., 1993; Simpson et al., 1988; Anzai et al., 1997; 
Gonzalez-Quesada and Frangogiannis, 2009; de Lemos et al., 2007; Christia 
and Frangogiannis, 2013).  To determine the effects of Grem2 gain-of-function 
on cardiac recovery, we compared cardiac functional parameters among WT 
controls, TGGrem2 mice by M-mode echocardiography at various time points after 
MI (Figure 25).   
Our data show that TGGrem2 mice have better preserved cardiac function 
compared to WT littermate controls of C57BL/6 background, as evidenced by 
higher fractional shortening (FS) and ejection fraction (EF) values 21 days after 
MI (Fig. 25A).  
Functional recovery in TGGrem2 mice was due to preservation of both 
systolic and diastolic dimensions with lower overall values compared to WT 
control mice at day 21 after MI (Figure 25B). TGGrem2 mice have comparable 
ventricular dimensions and functional values to corresponding WT control mice at 
baseline (Figure 25B).  These data indicate that Grem2 levels directly correlate 
with functional recovery after acute MI.  Original images from M-mode 
echocardiography are shown in Figure 25C.   
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Systemic Grem2 administration attenuates inflammation after MI  
The results obtained in TGGrem2 mice suggest that Grem2 is sufficient to 
attenuate cardiac tissue inflammation after ischemic injury.  To test whether this 
activity is confined to a specific time window after MI and does not depend on 
structural or functional changes caused by permanent Grem2 overexpression in 
the heart of TGGrem2 mice, we injected WT mice intraperitoneally with Grem2 
protein at day 2, 3, and 4 after MI, during the critical time window of the 
inflammatory phase, isolated hearts at day 5 after MI, prepared single cell 
suspensions of non-cardiomyocyte cells and performed flow cytometry using 
antibodies recognizing specific immune cell types.  As shown in Figure 26A, 
there was a significant decrease in the leukocytes (CD45+), monocytes (Ly6C+), 
and macrophages (F4/80+) as compared to saline-injected control mice (original 
flow graphs in Figure 26B).  These results demonstrate that the anti-
inflammatory phenotype in TGGrem2 after MI can be recapitulated by systemic 
administration of Grem2 protein during the inflammation phase of cardiac tissue 
repair.  We were also able to confirm that Grem2 exerted direct effects in the 
hearts of as evidenced by a decrease in Id2 gene induction 5 days post-MI 
(Figure 26C).  
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Discussion 
 Gain of Grem2 function resulted in a decrease in cell adhesion molecule 
induction as well as inflammatory cell infiltration post-MI, phenotypes opposite to 
what was seen in the Grem2 loss of function animal.  Taken together, the data 
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presented here demonstrate that Grem2 is both necessary and sufficient for the 
regulation of the inflammatory response following a myocardial infarction.  The 
capability of Grem2 to augment the inflammatory response subsequently proved 
to be beneficial for functional cardiac recovery. Grem2 also appears to be playing 
a direct role on the inflammatory response, since the injection of Grem2 protein 
during the short time window that is the inflammatory response, lead to a 
decrease in inflammatory cell infiltrate.  Altogether demonstrating that two 
independent methods of Grem2 delivery lead to an improved cardiac recovery.   
Despite the fact that our data suggest Grem2 inhibits the magnitude of 
inflammation by decreasing the number of infiltrating inflammatory cells, the 
possibility remains that Grem2 reduces inflammation by increasing the induction 
of signals that actively lead to its resolution.  Our current data, illustrating that the 
induction cytokines involved in activating the resolution of inflammation (Tgfβ and 
Il-10) is decreased in our gain of Grem2 function model, suggest that this is not 
the case.  However, we did not assess the presence of reparative macrophages 
or regulatory T-cells.  Future analysis to determine if Grem2 directly regulates the 
resolution of inflammation could include determining if Grem2 injection during the 
inflammatory phase changes the induction levels of the aforementioned 
resolution cytokines as well as determine if changes in Grem2 expression lead to 
changes in the presence of reparative macrophages or regulatory T-cells via flow 
cytometry.   
 The ability to treat mice with exogenous Grem2 protein several days 
following the MI, demonstrates that Grem2 has translational and therapeutic 
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potential.   Most current therapies are administered within the first several hours 
after the MI (McMurray, 2010).  Since Grem2 acts directly on decreasing the 
extent of the inflammatory phase of recovery while inflammation is occurring, it 
has the potential to offer a treatment plan that can continue after the first several 
hours following an acute cardiac injury.  It remains to be seen however, what the 
long-term effects are of Grem2, for example if administration of Grem2 during 
inflammation leads to improved recovery during the later stages of repair.  
Further investigations into any long-term effects as well as the ability of Grem2 
administration to improve cardiac functional recovery are ongoing, for example if 
the administration of Grem2 post-MI leads to an improved functional recovery 21 
days post-MI.   
 Previous clinical trials testing whether blocking inflammation improves 
outcomes have so far produced mixed results.  For example, inhibitors of the 
complement system, TNF, or integrins required for immune cell binding showed 
no significant improvement of infarct size and MI outcomes (Christia and 
Frangogiannis, 2013).  Glucocorticoids actually had severe adverse effects, likely 
due to their interference with functions that are essential for healing (Roberts et 
al., 1976).  On the other hand, inhibitors of the P-selectin antagonist inclacumab 
(Tardif et al., 2013), did show promising results, indicating that moderating 
inflammation can be beneficial for cardiac repair after MI.  This work 
demonstrates a novel method of regulating the inflammatory phase without 
targeting direct components of the pathway.  It should also be noted that the 
ability of Grem2 to modulate the inflammatory response could have vast 
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implications. Previous genome wide association studies (GWAS) have correlated 
Grem2 with the human response to the smallpox vaccine (Hindorff et al., 2009; 
Ovsyannikova et al., 2012).  Therefore, our findings could be translatable to 
various inflammatory disease states besides the inflammatory response following 
an acute cardiac injury.  
In order to generate a therapeutic target based on the function of Grem2, 
a comprehensive understanding of its mechanism of action is required.  Although 
Grem2 is classically known to be a BMP antagonist, it contains a unique 
structure.  Therefore it has the potential to have a novel mechanism of action. 
Previous work demonstrating the pro-inflammatory activity of BMP signaling has 
shown to act through the non-canonical activation of NFκB (Csiszar et al., 2006).  
Therefore further analysis is needed in order to determine if canonical BMP 
signaling is responsible for the pro-inflammatory phenotype and if Grem2 
regulates canonical BMP signaling in the context of cardiac recovery.  The role of 
canonical BMP signaling in cardiac repair is addressed in the subsequent 
chapter.  
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CHAPTER V 
 
GREM2 REGULATES CANONICAL BMP SIGNALING POST-MI 
 
 
Introduction 
 BMP signaling occurs through binding and activation of the type 1 and 
type 2 receptor complexes.  During canonical signaling, receptor Smads 
(Smad1/5/8) become phosphorylated and then form a complex with co-Smads 
that then translocate to the nucleus and activate target gene transcription such 
as IDs.  BMP signaling is known to be important for cardiac and vascular 
development and has also been implicated in vascular disease (Lowery and de 
Caestecker, 2010).   
 Previous work has implicated that BMP signaling is also induced following 
a cardiac injury.  However, its role during cardiac repair is not entirely 
understood. Using gene expression and immunofluorescence analysis, we found 
that BMP signaling is activated in border zone cardiomyoctyes during the 
inflammatory phase of recovery.  Due to the fact that I determined that a BMP 
signaling antagonist, Grem2, regulates the magnitude of inflammation following 
an MI (CHAPTERS III and IV) and since the Hatzopoulos laboratory has 
previously shown that Grem2 regulates canonical BMP signaling in vivo during 
development (Muller et al., 2013), I therefore wanted to determine if Grem2 
regulates the canonical BMP signaling pathway in the context of cardiac repair. 
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We hypothesized that canonical BMP signaling is responsible for increasing the 
magnitude and spread of inflammation following a myocardial infarction.    
 
Materials and methods 
Generation of genetically engineered Grem2 mice 
See CHAPTERS III and IV. 
 
Experimental MI and administration of Grem2 protein and DMH1 
See CHAPTER II. 
For administration of DMH1 (Sigma), Grem2-/- mice were injected IP with 
13 µg DMH1 (Helbing et al., 2011) per gram of body weight or vehicle (DMSO) 
once per day at 2, 3 and 4 days following MI as previously described (Hao et al., 
2014). 
 
RNA analysis by Reverse Transcription and quantitative Polymerase Chain 
Reaction (RT-qPCR) 
See CHAPTER II. The sequences of gene-specific primers for this chapter 
have also been included in Table 1.  
 
Immunofluorescence and immunohistochemistry analyses  
See CHAPTER II. 
Primary antibodies used for IF analysis were as follows: rabbit monoclonal 
anti-mouse p-Smad1/5/8 (Cell Signaling; 1:50, Cat. No. 9511), mouse 
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monoclonal anti-mouse MF20 (Developmental Studies Hybridoma Bank; 1:5, 
Cat. No. MF 20, RRID:AB_2147781), rabbit monoclonal anti-Id2 (Biocheck Can. 
No. BCH-3/#9-2-8) and rat monoclonal anti-mouse CD45 (BD Pharmingen; 
1:100, Cat. No. 550539).  
p-Smad1/5/8+ cardiomyocytes were quantified using ImageJ 1.46r (NIH) 
color thresholding, as a percentage of cells double positive for MF20 and p-
Smad1/5/8 amongst all DAPI positive cells in the viewing field; at least 4 viewing 
fields were used for calculations.  N=3 mice for each group.  
 
Flow Cytometry 
 See CHAPTER III. 
 
Statistical Analysis 
Statistical analysis was performed using GraphPad Prism software.  Data 
are represented as the mean ± SEM.  Student’s two-tailed unpaired t-test was 
used for comparison between two groups, one-way ANOVA was used to 
compare multiple groups, and two-way ANOVA was used to compare gene 
induction in each mouse model over time.  Dunnett’s and Bonferroni’s multiple 
comparisons test was used post-hoc.  *P<0.05, **P<0.01, ***P< 0.001, 
****P<0.0001 were considered significant.  
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Results 
Changes in Grem2 expression leads to changes in BMP pathway component 
induction post-MI 
 Grem2-/-, TGGrem2, and their corresponding WT siblings underwent 
permanent LAD ligation and whole heart RNA was isolated at the indicated days 
after MI. qPCR analysis showed that changes in Grem2 expression led to 
changes in the induction of BMP ligands.  Namely, the loss-of Grem2 function 
resulted in an increase in Bmp2 and Bmp4 induction, with no significant changes 
in Bmp6 induction.  However the gain-of Grem2 function significantly increased 
and decreased the induction of Bmp4 and Bmp6 respectively, with no change in 
the induction of Bmp2 (Figure 27A).  
Dynamic changes to BMP antagonist induction also occurred with 
changes in Grem2 expression.  The antagonists that exhibited a modest 
induction in WT mice post-MI were analyzed (Dan and Noggin). The expression 
level of Grem2 directly correlated with the induction of Dan. However the loss-of 
Grem2 resulted in an increase in the induction of Noggin and gain-of Grem2 
function did not affect Noggin levels (Figure 27B).   
To assess if the level of Grem2 expression affects the induction levels of 
BMP signaling target genes, Id2 induction was analyzed since this was the only 
BMP target gene that exhibited a significant increase in WT mice post-MI.  As 
expected, levels of Grem2 expression inversely correlated with the induction of 
Id2 at 7 days post-MI (Figure 27C).  These results suggest that Grem2 is acting 
as a canonical BMP signaling antagonists during this time.   
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However, despite the fact that dynamic changes occur in these BMP 
pathway component genes, most genes do not exhibit effects that are dependent 
upon Grem2 expression levels.  Therefore it is difficult to make any conclusion 
that Grem2 affects the expression of these genes, which is corroborated by their 
timing of peak induction in WT mice post-MI (CHAPTER II).  It is more likely that 
	  	  78	  
the changes observed are due to systemic changes that occur in order to 
compensate for the level of Grem2.   
 
Grem2 regulates canonical BMP signaling in border zone cardiomyocytes  
Grem2 is known to inhibit the canonical BMP signaling pathway by 
preventing BMP ligand-mediated phosphorylation of Smad1/5/8 and activation of 
target gene transcription (Nolan et al., 2013; Sudo et al., 2004).  To test whether 
Grem2 regulates canonical BMP signaling in the heart, we analyzed cardiac 
tissue sections at day 7 after MI from WT, Grem2-/- and TGGrem2 mice.  IF staining 
with antibodies recognizing expression of the target gene Id2 showed that Id2 is 
increased in the Grem2-/- animals compared to WT controls, however the 
increase in Id2+ cells could be due the increase in the number of what are likely 
inflammatory cells in the infarct area (Figure 28A).  However, despite the fact 
that the BMP target gene Id2 is present in infiltrating cells, leukocytes (CD45, 
red) do not show active canonical BMP signaling activity (p-Smad1/5/8, green), 
demonstrating that inflammatory cells are not the target cells of Grem2 (Figure 
28B).  IF staining with antibodies recognizing the phosphorylated, i.e., active 
form of Smad1/5/8, showed that intensity of p-Smad1/5/8 was increased in 
Grem2-/- mice and decreased in TGGrem2 hearts as compared to WTs (Figure 
28C,D). However, unlike the early stages after MI (Figure 10D), we did not 
detect p-Smad1/5/8 in endothelial cells. 
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The p-Smad changes overlap with the Grem2 expression domain 
(Chapter II) in peri-infarct area cardiomyocytes, suggesting Grem2 acts as a 
barrier to limit the infiltration of inflammatory cells into neighboring, relatively 
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healthy cardiac tissue.  In agreement with this notion, we observed inflammatory 
cells in the peri-infarct tissue past the infarct border zone in Grem2-/- hearts, 
whereas inflammatory cells were confined within the infarct area in WT controls 
(Figure 28E).  
 
Inflammatory cell infiltration post-MI is regulated by canonical BMP signaling 
To test whether the increased inflammatory cell infiltration is due to p-
Smad1/5/8 mediated signaling, we injected Grem2-/- mice with the canonical BMP 
signaling chemical inhibitor DMH1 (Ao et al., 2012) and vehicle control (DMSO) 
on day 2, 3, and 4 after MI, which correspond to the peak days of inflammation.  
DMH1 is highly specific to canonical BMP signaling without known off-target 
effects, as tested in various mouse disease models (Owens et al., 2015; Ao et 
al., 2012; Hao et al., 2014; Sun et al., 2013).  We found that DMH1 treatment 
rescued the pro-inflammatory phenotype in Grem2-/- mice.  Flow cytometry 
analysis at day 5 after MI showed that treated Grem2-/- hearts had a dramatic 
decrease in infiltrated leukocytes (CD45+), monocytes (Ly6C+), and 
macrophages (F4/80+) as compared to vehicle injected controls (Figure 29).   
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Discussion 
Our data indicate that BMP signaling plays an important role in the cardiac 
repair process after MI.  Although it was known that BMP ligands cause 
cardiomyocyte apoptosis during the early stages of ischemia/reperfusion injury, 
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to our knowledge, ours is the first study to show that canonical BMP signaling 
activation after MI controls the magnitude of the inflammatory response.   
Specifically, our data indicate that in the absence of Grem2, increased p-Smad-
mediated BMP signaling in the infarct border-zone is responsible for excessive 
infiltration of inflammatory cells.  Canonical BMP signaling is also responsible for 
limiting inflammatory cell infiltrate, since canonical BMP inhibition rescues the 
loss-of-Grem2-phenotype.  Taken together, inhibition of canonical BMP signaling 
is required to limit the extent and spread of the inflammatory response following 
an acute cardiac injury, and Grem2 may be critical in reducing and eventually 
stopping the recruitment of circulating leukocytes. Therefore, recognizing the role 
of BMP signaling and the mechanisms of its inhibition in cardiac tissue repair 
after MI may offer novel insights in the cardiac healing process and provide new 
ways to regulate inflammation in a physiological manner.  
Due to the wide interest in regulating BMP signaling in bone fractures, 
osteoporosis and cancer (Gao et al., 2012; Hayashi et al., 2009; Khosla et al., 
2008; Kua et al., 2012; Sneddon et al., 2006; Tang et al., 2013; Yan et al., 2014), 
a number of chemical compounds and peptides, to either promote or hinder BMP 
signaling, are being developed for clinical use (Cao et al., 2014; Sanvitale et al., 
2013; Yu et al., 2008). Our findings may facilitate future repurposing of these new 
pharmacological resources for potential treatment of MI patients to expand 
current strategies that aim to restore circulation to infarcted areas with 
thrombolytics and percutaneous interventions.  
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Despite our current data demonstrating that Grem2 limits inflammation by 
inhibiting canonical BMP signaling post-MI, the possibility remains that other 
pathways could be regulated by changes in the expression of Grem2.  Our 
previous work in mouse embryonic stem cells illustrated Grem2 treatment 
resulting in a counter activation of the non-canonical BMP signaling component, 
JNK (Tanwar et al., 2014), therefore Grem2 is capable of acting in ways that 
differ from its classical role as a canonical BMP antagonist.  The ability of Grem2 
to act in this way could lead to downstream effects on other pathways during the 
cardiac repair process, such as the JNK pathway, the Wnt pathway, and the TAK 
pathway, all of which have been implicated to be either regulated by Grem2 or 
BMP signaling as well as induced post-MI (Matsumoto-Ida et al., 2006; Pachori 
et al., 2010; Paik et al., 2015; Wu et al., 2015; Yamaguchi et al., 1999).    
Determining if Grem2 has an effect on the activation of these pathways during 
cardiac repair will be the topic of future investigations.   
Besides determining that BMP signaling is involved in the regulating the 
inflammatory response post-MI, the context and exact mechanism of action 
remains to be elucidated.  Since pro-inflammatory cell adhesion molecules bring 
circulating leukocytes into the site of injury, it is possible that Grem2 limits the 
magnitude of inflammation through inhibiting the pro-inflammatory effect of BMP2 
in these cells. Molecular insight into how exactly Grem2 limits inflammation is the 
topic of the subsequent chapter.   
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CHAPTER VI 
 
GREM2 INHIBITS THE PRO-INFLAMMATORY EFFECT OF BMP2 ON 
ENDOTHELIAL CELLS 
 
 
Introduction 
 BMP signaling has previously been shown to be pro-inflammatory in 
several vascular disease states (Simões Sato et al., 2014; Sorescu et al., 2003).  
The majority of this work provides evidence that BMP signaling exerts these pro-
inflammatory effects on endothelial cells, specifically by increasing their 
expression of pro-inflammatory cell adhesion molecules (Csiszar et al., 2005, 
2006; Sucosky et al., 2009). BMP signaling antagonists such as BMPER and 
Noggin are able to inhibit this effect (Helbing et al., 2011; Koga et al., 2013; Pi et 
al., 2012).  
 Work described in the previous chapters demonstrates that canonical 
BMP signaling is induced during the inflammatory phase of cardiac repair within 
border zone endothelial cells and later in border zone cardiomyocytes, and is 
responsible for increasing the magnitude of inflammation as evidenced by loss 
and gain of function models of the BMP antagonist Grem2 as well as through 
injection of the canonical BMP signaling inhibitor DMH1.  Grem2 is also induced 
directly after the peak of BMP2 ligand induction.  Therefore Grem2 exerts 
autocrine effects on these cardiomyocytes in order to limit inflammation. However 
BMP ligands and antagonists, including Grem2, are secreted proteins and are 
	  	  86	  
likely to have paracrine effects on neighboring cell types.  Therefore in order to 
gain a greater insight on the molecular interplay between BMP signaling, Grem2, 
and inflammation, we used a human endothelial cell line in order to delve into the 
activation of the inflammatory response through the induction of pro-inflammatory 
cell adhesion molecules present on these cell types. 
 
Materials and methods 
Cell culture 
Human Microvascular Endothelial cells (HMECs) (Ades et al., 1992) were 
kindly provided by Dr. Sergey Ryzhov.  Cells used for experiments were between 
the third and fourth passages and cultured in 199 media (Gibco 11150) 
containing 15% FBS, 10 U/ml Heparin (Sigma), and 30 µg/ml endothelial cell 
growth supplement (Biomedical Technologies).  Cells were grown in full growth 
serum and then seeded in 12-well plates.  Prior to growth factor addition, cells 
were incubated with serum starvation media (same as normal media with 1% 
FBS) over night.   Cells were subsequently treated with rhTNF (R&D; 10 ng/ml), 
rhBMP2 (R&D; 100 ng/ml-250 ng/ml), Grem2 (100 ng/ml), and DMH1 (10µM) or 
the equivalent volume of vehicle solution (PBS or DMS0).  After 4 hours, 24 
hours, or 48 hours of treatment, cells were lysed for RNA extraction.  Data is 
representative of at least two independent experiments.   
For binding assays, HMEC cells were grown for three days until they 
reached monolayer confluency (3 x 104 cells/well within a 96-well plate).  Calcein 
AM labeled (1 µM, 30 min) human monocytes (THP-1 cells) were added to the 
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HMEC monolayer at a concentration of 10 x 104 cells per well (EC:THP-1 ratio – 
1:3) and incubated together for 30 minutes.  After incubation, non-adherent THP-
1 cells were aspirated off and the remaining cells were washed with PBS 5 times. 
The fluorescence intensity was measured using the Modulus microplate 
multimode reader. The number of adherent THP-1 cells was calculated from a 
calibration curve prepared using increasing concentrations (ranging from 0.1 to 
100 x 103 cells) of THP-1 cells. 300 ng/ml of BMP2, 100 ng/ml of Grem2 and 
100ng/ml of TNFα were used alone or combination for 24 hours.   
 
RNA analysis by Reverse Transcription and quantitative Polymerase Chain 
Reaction (RT-qPCR) 
See CHAPTER II. RNA was obtained from cells in culture using the 
RNeasy Mini Kit (Qiagen). The sequences of gene-specific primers for this 
chapter have also been included in Table 1.  
 
Statistical Analysis 
Statistical analysis was performed using GraphPad Prism software.  Data 
are represented as the mean ± SEM.  Student’s two-tailed unpaired t-test was 
used for comparison between two groups, one-way ANOVA was used to 
compare multiple groups, and two-way ANOVA was used to compare gene 
induction in each mouse model over time.  Dunnett’s and Bonferroni’s multiple 
comparisons test was used post-hoc.  *P<0.05, **P<0.01, ***P< 0.001, 
****P<0.0001 were considered significant. 
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Results 
Grem2 inhibits the pro-inflammatory effect of Bmp2 on endothelial cells  
The data described above indicate that secretion of Grem2 protein by peri-
infarct cardiomyocytes affects directly or indirectly the pro-inflammatory 
phenotype of cardiac endothelial cells and that canonical BMP signaling is 
induced in endothelial cells during the inflammatory phase.  Further gene 
expression analysis at various time points after MI showed that TN is induced 
first, followed by Bmp2 and then Grem2 (Figure 30A).  To investigate whether 
the sequential temporal induction patterns of the three genes after MI are linked; 
we tested the effects of TNFα, BMP2 and Grem2 on the human microvascular 
endothelial cell line HMEC-1.  We found that TNFα induces expression of E-
SELECTIN and BMP2, suggesting early pro-inflammatory cytokines contribute to 
the induction of the Bmp2 gene after MI in vivo (Figure 31 and Figure 30B).   
BMP2 in turn induces E-SELECTIN expression in endothelial cells as well as 
Grem2, suggesting BMP2 induces a negative regulatory loop to limit its own 
activity (Figure 30C, D).  
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To determine whether: a) BMP2 acts synergistically with TNFαand, b) 
Grem2 blocks the pro-inflammatory effect of BMP2 on endothelial cells, we 
treated HMEC-1 with TNFα, BMP2 and Grem2 in different combinations (Figure 
30E, Figure 32).  When protein factors were added alone, both TNFαand BMP2 
induced E-SELECTIN expression.  Co-stimulation with TNFα and BMP2 led to E-
SELECTIN induction levels higher than either factor alone, suggesting TNFα and 
BMP2 have a synergistic or additive effect.  Grem2 did not affect the TNFα 
induction of E-SELECTIN, but completely inhibited the BMP2 effect.   In similar 
fashion, co-incubation with TNFα, BMP2 and Grem2 specifically abrogated the 
BMP2 effect, reducing E-SELECTIN levels to those induced by TNFα treatment 
alone (Figure 30E).  In accordance with its function as a canonical BMP 
signaling antagonist, Grem2 blocked induction of BMP signaling target ID2, 
whereas TNFα alone had no effect on ID2 expression, although it reduced the 
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fold induction of ID2 by BMP2 (Figure 32).  Treating cells with the chemical 
inhibitor of canonical BMP signaling DMH1 showed similar effects as Grem2, 
indicating that that BMP2-induction of E-SELECTIN is due to activation of 
canonical BMP signaling (Figure 30F).   
 
To test the functional significance of the modulation of pro-inflammatory 
gene expression in endothelial cells by Grem2, we performed cell adhesion 
assays of monocytes to endothelial cells in vitro in collaboration with Dr. Sergey 
Ryzhov.  These assays showed that pre-incubation of endothelial cells with 
BMP2 increased adhesion of monocytes to endothelial cells and further 
enhanced the TNFα effect.  Incubation with Grem2 abolished the BMP2 effect, 
but not that of TNFα (Figure 30G).   In contrast, pre-incubation of monocytes 
with BMP2 and/or Grem2 had no effect on their adhesion to endothelial cells 
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(Figure 33).  Moreover, immunofluorescence analysis of infarct areas with 
antibodies recognizing p-Smad1/5/8 and CD45 to determine canonical BMP 
signaling activity in infiltrating inflammatory cells showed no detectable p-
Smad1/5/8 i.e., canonical BMP signaling in inflammatory cells, and this pattern 
did not change in the Grem2-/- mice (CHAPTER V, Figure 28B).   These data 
further support the idea that the primary cellular targets of Grem2 are the 
endothelial cells.   
 
Discussion 
In conclusion, we provide evidence to suggest that pro-inflammatory 
cytokines such as Tnfα induces Bmp2 and Bmp2 further increases the pro-
inflammatory phenotype of endothelial cells. BMP2 then induces the expression 
of its own antagonist, Grem2 as a negative feedback loop, thereby inhibiting 
canonical BMP signaling and the positive effect of Bmp2 on inflammatory gene 
expression.  
Histological analysis demonstrated that Grem2 as well as canonical BMP 
signaling components are produced in peri-infarct cardiomyocytes, however 
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canonical BMP signaling is also present in endothelial cells (CHAPTERS II and 
V). Therefore, Grem2 acts both in an autocrine fashion to inhibit p-Smad 
activation in cardiomyocytes, as well as in a paracrine fashion to suppress 
expression of the pro-inflammatory genes in adjacent endothelial cells.  
This induction of Grem2 appears to be an integral part of an orchestrated 
sequence of events that regulates the inflammatory response.  Our in vitro 
analyses suggest that this sequence starts with induction of Bmp2 by Tnfα, which 
is released shortly after cardiac tissue injury.  Bmp2 then further increases the 
Tnfα effect in the induction of pro-inflammatory cell interaction membrane 
proteins in endothelial cells, as the Tnfα effects decrease.  The pro- inflammatory 
action of Bmp2 is then blocked by Grem2, which itself is induced by Bmp2, thus 
forming a negative regulatory loop.  This concept is supported by in vivo data, 
which show sequential induction of Tnfα, Bmp2 and Grem2 after MI, each 
approximately 24 hours apart.  The in vitro assays that show BMP2 acts on 
endothelial cells to promote cell adhesion of monocytes, the consistent changes 
in the number of inflammatory cells across a wide spectrum of various immune 
cell types, and histological analyses showing minimal changes in BMP signaling 
in infiltrating leukocytes, all suggest that the main cellular target of Grem2 in the 
regulation of the inflammatory response in the heart are the endothelial cells.  
However, at present we cannot exclude that Grem2 may also affect the 
inflammatory cell differentiation, activation or mobilization prior to their 
recruitment in the infarct area.  
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We have previously shown that Grem2 promotes the cardiogenic potential 
of mouse ES cells (Tanwar et al., 2014).  Interestingly, we found that Grem2 has 
distinct biological effects from other BMP antagonists such as Noggin, Cerberus-
like 1 and Dan on cardiac differentiation of ES cells, suggesting a Grem2-specific 
and unique mechanism of BMP signaling regulation (Tanwar et al., 2014). While 
the mechanism for how Grem2 blocks BMP-ligand receptor interactions is 
unknown, it is likely that structural differences of the antagonists give rise to 
distinct binding strategies.  We currently test whether the unique structural 
arrangement of Grem2 is also critical for its function in cardiac repair.  Future 
biochemical analyses may identify critical structural motifs, which could be 
exploited to design molecules that would mimic the Grem2 biological effects in 
the attenuation of inflammation.   
To summarize the data presented thus far, we have determined a 
mechanism whereby Grem2 limits the magnitude and spread of inflammation 
post-MI by inhibiting canonical BMP signaling, which in turn inhibits the pro-
inflammatory effect of BMP2 in the context of cardiac repair following an acute 
injury.  Our data also suggests that the magnitude of inflammation has a direct 
correlation to cardiac functional recovery.  However, it is still unclear if Grem2 
affects the cellular processes that occur during the later stages of recovery.  
Insight into the affect of Grem2 on cellular proliferation as well as fibrosis 
formation will help determine how Grem2 affects these stages and is the topic of 
the investigations in the following chapter.    
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CHAPTER VII 
 
THE ROLE OF GREM2 DURING THE PROLIFERATIVE PHASE OF 
RECOVERY POST-MI 
 
 
Introduction 
 The cardiac repair process that occurs following an acute injury such as a 
myocardial infarction consists of several defined phases, the inflammatory phase, 
the proliferative phase, and the remodeling phase.  After inflammation clears 
cellular debris, granulation tissue begins to be deposited, consisting of reparative 
macrophages and proliferating endothelial cells as well as fibroblasts.  It is due to 
these populations of proliferating cells gives that this stage of recovery is called 
the proliferative phase.  After the granulation tissue is deposited, it eventually 
forms into a mature collagen based scar.  It is the presence of this dense 
inflexible scar that leads to cardiac remodeling and heart failure (Boudoulas and 
Hatzopoulos, 2009; Frangogiannis, 2008; Virag and Murry, 2003).   
 The Hatzopoulos laboratory has previously determined that other cellular 
processes, namely endothelial to mesenchymal transition (EndMT), play an 
important part of the proliferative phase of recovery (Aisagbonhi et al., 2011), as 
well as found that the canonical Wnt pathway regulates post-infarct angiogenesis 
and fibrosis (Paik et al., 2015).  Aside from Wnt signaling, Tgfβ has also been 
implicated in the regulation of epithelial to mesenchymal transition (EMT) and 
fibrosis post-MI (Shinde and Frangogiannis, 2014; Zeisberg et al., 2007). Due to 
the fact that Grem2 has previously been linked to Wnt signaling and since its 
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close paralog Grem1 has been shown to be pro-fibrotic through promoting Tgfβ, 
we wanted to determine if Grem2 plays a role during the proliferative phase of 
cardiac recovery (Im et al., 2007; Li et al., 2012; Rodrigues-Diez et al., 2012).   
 
Materials and methods 
Generation of genetically engineered Grem2 mice 
 See CHAPTERS III and IV. 
 
Experimental MI 
See CHAPTER II. 
 
RNA analysis by Reverse Transcription and quantitative Polymerase Chain 
Reaction (RT-qPCR) 
See CHAPTER II.  The sequences of gene-specific primers for this 
chapter have also been included in Table 1.  
 
Immunofluorescence analyses  
See CHAPTER II. 
Primary antibodies used for IF analysis were as follows: rat monoclonal 
anti-mouse CD31/PECAM1 (BD Pharmingen; 1:100, Cat. No. 553370), rabbit 
anti-mouse Ki67 (Abcam 1:100 Ab15580), and rabbit anti-mouse collagen I 
(Abcam 1:400 Ab292).  
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Ki67+ cells were quantified using ImageJ 1.46r (NIH) color thresholding, as 
a percentage of cells double positive for DAPI and Ki67 amongst all DAPI 
positive cells in the viewing field; at least 4 viewing fields were used for 
calculations.   
 
Flow Cytometry 
 See CHAPTER III. 
 
Statistical Analysis 
Statistical analysis was performed using GraphPad Prism software.  Data 
are represented as the mean ± SEM.  Student’s two-tailed unpaired t-test was 
used for comparison between two groups, one-way ANOVA was used to 
compare multiple groups, and two-way ANOVA was used to compare gene 
induction in each mouse model over time.  Dunnett’s and Bonferroni’s multiple 
comparisons test was used post-hoc.  *P<0.05, **P<0.01, ***P< 0.001, 
****P<0.0001 were considered significant.  
 
Results 
Gain of Grem2 function results in increased endothelial cell gene expression and 
proliferation post-MI 
 Granulation tissue formation is marked by endothelial cell proliferation that 
acts to re-vascularize the infarcted tissue.  To determine if Grem2 affects this 
phase of recovery, Grem2-/-, TGGrem2, and their corresponding WT siblings 
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underwent permanent LAD ligation and whole heart RNA was isolated at the 
indicated days after MI. qPCR analysis showed that gain of Grem2 function led 
an increase in the induction of genes that are involved in blood vessel formation. 
Vascular markers such as Angiopoietin 1 (Ang1) and Ve-cadherin, exhibited 
higher levels of induction in TGGrem2 animals compared to their respective WT 
counterparts. Conversely, the phenotype seen in the Grem2-/- mice was modest 
and not statistically significant, demonstrating that Grem2 is not required for the 
induction of angiogenic genes post-MI.  Therefore the overexpression of Grem2 
specifically results in a positive effect on vascular formation (Figure 34A).   
To determine if Grem2 affects the proliferation of these cells, histological 
analysis using antibodies for Ki67, a marker of proliferation, and CD31, a marker 
for endothelial cells, was conducted in Grem2-/-, TGGrem2, and WT controls at day 
5 post-MI.  The overexpression of Grem2 resulted in an increase in Ki67+ 
endothelial cells in the infarct border zone, whereas the loss of Grem2 did not 
result in a significant change in the number of proliferating cells (Figure 34B, C).   
Taken together with the data mentioned above, Grem2 is not necessary for the 
induction of the vascular gene program or proliferation of endothelial cell 
populations, but its overexpression promotes vascular integrity post-MI.   
Flow cytometry of cardiac cells 5 days after MI, excluding cardiomyocytes, 
was used to determine if changes seen in gene programs and proliferation 
resulted in changes to the number of cells present in cardiac tissue at this time 
point post-MI.  Grem2-/-, TGGrem2, and WT controls did not exhibit a significantly 
different amount in the number of CD31+ endothelial cells (Figure 34D).  
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However, the possibility remained that BMP signaling could be responsible for 
regulating the level of cells present post-MI.  To test whether the number of 
endothelial cell populations is correlated with p-Smad1/5/8 mediated signaling, 
we injected Grem2-/- mice with the canonical BMP signaling chemical inhibitor 
DMH1 (Ao et al., 2012) and vehicle control (DMSO) on day 2, 3, and 4 after MI.  
DMH1 is highly specific to canonical BMP signaling without known off-target 
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effects, as tested in various mouse disease models (Owens et al., 2015; Ao et 
al., 2012; Hao et al., 2014; Sun et al., 2013).  We found that DMH1 treatment did 
not change the number of endothelial cells present in Grem2-/- mice (Figure 
34E).  Therefore, our current data demonstrates a positive role for Grem2 in 
vascular biology. However, it is not necessary nor results in changes to the 
actual vasculature of the heart post-MI.  
 
The Wnt pathway is induced during the proliferative phase of recovery and is 
affected by Grem2 expression levels 
Work previously published by our laboratory demonstrates that canonical 
Wnt signaling is induced during the proliferative phase of cardiac recovery 
(Aisagbonhi et al., 2011).  Using qPCR analysis, we subsequently determined 
that a particular canonical Wnt ligand, Wnt10b demonstrates a peak induction 
that follows the induction of known components of this phase of repair such as 
Tgfβ1 (Figure 35A, from Paik et al., 2015).  Other Wnt ligands were analyzed via 
qPCR, however Wnt4 was the only ligand found to be robustly induced post-MI 
(Figure 35B).   
Since the overexpression of Wnt10b conferred positive effects on the 
recovery process through the induction of angiogenesis (Paik et al., 2015), we 
investigated if changes in the expression of Grem2 resulted in changes to the 
induction of Wnt pathway components.  Grem2+/-, Grem2-/-, TGGrem2, and WT 
mice underwent permanent LAD ligation and whole heart RNA was isolated at 
the indicated days post-MI.  qPCR analysis showed that changes in Grem2 
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expression were directly correlated with levels of Wnt4 induction (Figure 35B).  
To further explore the effect of Grem2 on Wnt signaling activation, the induction 
level of the canonical Wnt target gene Axin2 post-MI was analyzed in Grem2-/-, 
TGGrem2, and their corresponding WT siblings.  Interestingly, the loss-of Grem2 
did not affect Axin2 induction levels, and the gain-of Grem2 function resulted in a 
complete lack of Axin2 induction (Figure 35C).  Taken together, these data 
demonstrate that Grem2 directly affects the induction levels of Wnt ligands, 
however it appears to have a negative effect on the activation of canonical Wnt 
signaling.   
 
Grem2 does not affect scar formation post-MI 
  EndMT gene induction such as Vimentin was assessed via qPCR and was 
not affected by the overexpression of Grem2.  The loss of Grem2 function 
however, resulted in the significant increased induction of Vimentin post-MI 
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(Figure 36A).  Genes that represent the mesenchymal or fibrotic pathway such 
as Fsp-1 and αSma exhibited dynamic changes in each of the Grem2 models. 
Fsp-1 was increased in both the loss-of and gain-of function models, the cause of 
which likely differs in each model (Figure 36B).  The enhanced inflammatory 
response in the loss-of-function model could lead to an increase in the induction 
of pro-fibrotic genes.  However, Grem2 may also itself be pro-fibrotic, due to the 
fact that the literature suggests its close paralog Grem1, is pro-fibrotic in the 
heart as well as in other disease states. Therefore, an increase in Grem2 
expression would lead to an increase in the induction of fibroblasts (Koli et al., 
2006; Li et al., 2012; Mueller et al., 2013; Rodrigues-Diez et al., 2012)(kidney 
paper, EMT paper).  Conversely, the induction levels of the myofibroblast marker 
αSma exhibited an inverse correlation with the expression levels of Grem2 
(Figure 36C).  Therefore the induction of a myofibroblast gene program may be 
directly affected by the extent of the inflammatory response post-MI.   
Flow cytometry as described above, was used to determine if Grem2 
regulated the number of fibroblasts present in cardiac tissue post-MI.  Grem2-/-, 
TGGrem2, and WT controls did not contain different amounts of CD140a+ 
fibroblasts (Figure 36D).  The inhibition of canonical BMP signaling via DMH1 
treatment also did not change the number of fibroblasts present in Grem2-/- mice 
(Figure 36D).  Therefore, neither Grem2 nor the inhibition of canonical BMP 
signaling changes the number of fibroblasts present in the heart post-MI, despite 
the changes seen at the gene induction level.   
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Due to the effect of Grem2 on the inflammatory phase of recovery as well 
as its effect on fibroblast gene induction, molecular and histological analysis was 
conducted in order to measure scar component gene induction, scar morphology, 
and scar size.  Grem2-/-, TGGrem2, and WT mice underwent permanent LAD 
ligation and whole heart RNA was isolated at the indicated days post-MI. qPCR 
analysis showed that both the loss-of and gain-of Grem2 function resulted in an 
increased induction of pro-Collagen Ia1 (Collagen I) at days 7 and 3 post-MI 
respectively (Figure 36E). 
Immunofluorescence using antibodies for Collagen I and CD31 was 
conducted in Grem2-/-, TGGrem2, and WT controls 7 days post-MI to determine if 
the changes at the RNA level can be appreciated at the histological level.  
Collagen I intensity and density is overall comparable between the groups 
(Figure 36F).  The lack of any obvious difference in collagen intensity at day 7 
post-MI could be an artifact from the timing of the analysis, since the scar is only 
beginning to mature at this time.  In order to obtain greater insight into any 
possible changes in scar formation caused by Grem2, tissue sections from 
Grem2-/-, TGGrem2, and WT mice were analyzed using Masson’s Trichrome 
staining at 21 days post-MI, when the scar is thought to be mature.  The overall 
size of the scar was relatively comparable among all mouse groups, despite an 
obvious increase in cardiac hypertrophy in Grem2-/- hearts (Figure 36G).  Taking 
a closer look at the morphology of the scar, it did appear that the scar in Grem2-/- 
mice is more loosely compact compared to WT counterparts and could be a 
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result of the overactive inflammatory response (Figure 36H).  Therefore, current 
data suggest that Grem2 does not regulate scar size post-MI.   
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Grem2 affects cardiac remodeling  
 Following the proliferative phase of repair is cardiac remodeling.  The 
extent of remodeling is primarily determined by the extent of the inflammatory 
and/or proliferative phases of recovery.  Furthermore, there is a set of genes that 
are considered to be indicative of cardiac remodeling.  In order to determine if 
Grem2 affects the cardiac remodeling gene program, we assessed the induction 
of gene such as Mmp9, Nppa, Nppb, and β-MHC in Grem2-/-, TGGrem2, and their 
WT counterparts at 0, 7, and 21 days post-MI (de Lemos et al., 2001; Omland et 
al., 1996).  The genes demonstrated the same trend in both Grem2 loss of- and 
gain of- function models.  However, the direction of the trend was not consistent, 
meaning that the induction of certain genes was increased whereas others were 
decreased (Figure 37).  Therefore, it is clear that Grem2 plays a role in cardiac 
remodeling; the nature of its role however requires further investigation. 
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Discussion 
 In conclusion, Grem2 promotes the proliferation of endothelial cells as well 
as the induction of pro-angiogenic gene programs.  However, Grem2 expression 
does not appear to be required for the proliferative phase of recovery since the 
loss- of-function model did not exhibit dramatic phenotypic changes, nor were 
there changes to the actual number of endothelial cells present in cardiac tissue 
at day 5 post-MI.  This is likely due to the fact that canonical BMP signaling is not 
responsible for regulating the presence of endothelial cells as demonstrated by 
the data obtained through the injection of DMH1. Therefore, Grem2 could be 
activating alternative pathways during the proliferative phase of repair, such as 
the JNK pathway, as we have previously demonstrated to occur during cardiac 
development (Tanwar et al., 2014).   
Subsequently, the fibrotic phase of repair exhibited a similar trend, where 
Grem2 promoted the expression of genes such as Fsp-1, however the number of 
actual fibroblasts were not changed by levels of Grem2 or through chemical 
inhibition of canonical BMP signaling. The scar size is also comparable between 
all experimental groups, and although changes in Grem2 expression led to 
changes in the cardiac remodeling gene program, it is unclear whether Grem2 
plays a positive or negative role during this phase of repair. 
Despite the dramatic changes seen during inflammation as a result of 
changes in Grem2 expression, the changes observed during the proliferative or 
remodeling phases do not correlate with the level of Grem2.  Taken together, 
these data suggest that the phenotype seen in cardiac function post-MI (shown in 
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Chapters III and IV) is specifically due to the effect of Grem2 on the inflammatory 
phase of repair.  This result is somewhat surprising, since the current belief in the 
field is that the extent of injury that occurs during the early phases of cardiac 
recovery, directly affects all the subsequent stages.  
It is important to note that there are several limitations present in the 
current analysis.  Conducting flow cytometry for endothelial cells and fibroblasts 
at day 5, may not be instructive, since that time point corresponds to the initiation 
of the proliferative phase of recovery.  Flow cytometry analysis at a later time 
point following myocardial infarction could be more informative for determining if 
Grem2 regulates cell populations present during later stages of cardiac repair.    
Due to the constitutive nature of the Grem2 gain of- and loss of- function 
animals, it is difficult to discern direct effects of Grem2 expression on the 
proliferative and remodeling phases of cardiac repair. Therefore, future 
experimentation including Grem2 treatment specifically during these phases in 
lieu of treatment during the inflammatory phase would be beneficial in discerning 
the specific role of Grem2.  The same is true for determining the role of canonical 
BMP signaling through injection of DMH1.   
In order to gain further mechanistic insight, in vitro models could ascertain 
the function of Grem2 during the proliferative and fibrotic stages of cardiac 
recovery.  Fibroblast and endothelial cells treated with Grem2 would provide 
information regarding the molecular pathways and specific phenotypes Grem2 
alters in these cell populations.  Namely, Grem2 treatment could be used to 
determine if it promotes proliferation, processes such as EndMT, and if it 
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promotes or inhibits the production of collagen in fibroblasts.  Such studies would 
also be instrumental in determining the target cell of Grem2 during the phases of 
cardiac repair following the inflammatory phase as well as determine if Grem2 
affects molecular pathways other than those regulated by BMP signaling, as 
addressed in the next chapter.   
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CHAPTER VIII 
 
HIGH THROUGHPUT SEQUENCING ANALYSIS IN THE CONTEXT OF THE 
LOSS OF GREM2 
 
 
Introduction 
 Grem2, also known as protein related to Dan and Cerberus is a member 
of the DAN family of BMP signaling antagonists.  Initially discovered just over a 
fifteen years ago (Pearce et al., 1999) most published work to date describes its 
mechanism of action to be through its role as a BMP antagonist (Ideno et al., 
2009; Kriebitz et al., 2009; Sudo et al., 2004).  However, Grem2 is a relatively 
unstudied protein and dimerizes in a head to tail dimer confirmation, making its 
structure unique among other BMP antagonists (Nolan et al., 2013).  Due to this 
unique tertiary structure, it remains possible that Grem2 has pleiotropic effects on 
previously undetermined pathways.  Therefore, an unbiased methodology is 
required to broaden the scope of investigation in order to determine if there are 
any novel associations, interactions, or pathways affected by the loss of Grem2 
function. 
RNA-seq analysis is a shotgun approach for measuring levels of genes 
expression, assessing the entire transcriptome of cells or tissues (Wang et al., 
2009).  To conduct a thorough and extensive analysis of any possible Grem2 
pathway interaction, we used this method of high-throughput sequencing on 
whole hearts isolated from Grem2-/- mice and WT counterparts both without injury 
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as well as day 7 post-MI, so that data can be collected pertaining to both the 
inflammatory and fibrotic response that occurs during cardiac repair.  
 
Materials and methods 
Generation of genetically engineered Grem2 mice 
See CHAPTERS III and IV.  
 
Experimental MI  
See CHAPTER II. 
 
RNA isolation from whole murine hearts 
Whole hearts were dissected at the indicated time points after MI, 
perfused to remove blood cells and RNA was obtained using TriZol Reagent 
according to the manufacturer’s instruction (Life Technologies).  
 
High throughput sequencing  
Sequencing was performed at Paired-End 75 base pair on the Illumina 
HiSeq 3000, where 45 million PF reads per sample. The initial gene association 
alignment data was done on CLC workbench using gene ontology.  An N=2 were 
used for the following: WT day 0, Grem2-/- day 0, WT day 7, and Grem2-/- day 
7.  WebGestalt Go enrichment analysis based on Entrez gene protein coding 
references was then conducted based on genes annotated using gene ontology 
gene symbols that had a 2-fold up-regulation post-MI and a p-value <0.05.  
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Pathways and genes that were induced in WT mice post-MI, Grem2-/- mice post-
MI, and those that were uniquely induced in Grem2-/- mice were analyzed.   
 
Results 
Using the Kallisto database, we found a short list of 12 genes that showed 
>2-fold differences between Grem2-/- mice and their WT counterparts at baseline.  
The majority of the genes (included in Table 4) encode ribosomal or 
mitochondrial proteins.  The lack of significant molecular differences between WT 
and Grem2-/- mice suggest no gross cardiac abnormalities exist at baseline.  
Initial pathway analysis results for genes induced post-MI are provided, where 
processes that are significantly induced are shown in red and first represent 
those pathways that are induced in WT mice post-MI (Figure 38A).  Although the 
analysis separates genes into different categories based on biological processes, 
molecular function, and cellular components, the genes that are significantly 
induced 2-fold largely overlap.  Within the immune system category, several 
TLRs and chemokine receptors are present, such as Tlr6, 7,8,9, Ccr1, 2,3, and 
Cxcr1, 2,3.  Chemokine ligands such as Ccl2, 3, Cx3cl1 as well as cytokines Tnf, 
Il-6, and Il-1β were also induced.  Endothelial cell adhesion molecules Icam1 and 
E-selectin also came up in this analysis, and other genes such as Tgfβ1, Timp1, 
myeloperoxidase, and thrombospondin not surprisingly exhibited significant 
changes in WT mice post-MI. The positive regulation of biological and cell 
processes categories included angiopoietin-like 4, Mmp9, Bmp2, Wnt4, Snai1 
and 2, Twist1, Vimentin, Col1a1 and angiotensin converting enzyme, thereby 
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representing genes involved in EndMT and fibrosis.  The heparin, carbohydrate 
derivative, and glycosaminoglycan categories were unique in WT mice post-MI, 
and contained several thrombospondin isoforms, Sfrp1, and latency binding 
protein 2, overall demonstrating Tgfβ and Wnt pathway regulation.  Taken 
together, the data from WT mice post-MI confirms what has been known about 
molecular pathways induced during cardiac repair.  
 Pathways significantly changed in Grem2-/- mice post-MI are shown in 
Figure 38B.  There are several categories that overlap with those present during 
normal cardiac repair, such as the immune system process and response.  
Within these several TLRs, chemokine receptors, chemokine ligands, and 
cytokines that were also present in WT mice such as Tlr6, 8,9, Ccr1, 2,3, Cxcr2, 
Cx3cl1 and Il-6 were also present in Grem2-/- mice post-MI.  Of note, as seen by 
our qPCR analysis, E-selectin and Tgfβ1 were also shown to be upregulated in 
this analysis.  Overlap within the positive regulation of biological processes 
category was seen through the presence of Snail1, Twist1, thrombospondin, 
Vimentin, and Col1a1.  The cation binding, catalytic activity, hydrolase activity, 
actin binding, and cell surface categories were uniquely altered in the case of the 
loss of Grem2 function.  The genes within these categories include activated 
leukocyte cell adhesion molecule (Alcam), XIAP associated factor 1 (Xaf1), 
immunoresponsive gene 1 (Irg1), alpha-fetoprotein (Afp), secretory leukocyte 
peptidase inhibitor (Slpi), lymphocyte specific 1 (Lsp1), and CD8a.  These data 
demonstrate that, genes that are induced in Grem2-/- mice post-MI include genes 
involved in cell adhesion, proteins specific to leukocytes and lymphocytes, and 
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interestingly, a factor associated with XIAP, a known non-canonical downstream 
target of BMP signaling (Yamaguchi et al., 1999).  The results confirm our current 
phenotypic data, where Grem2 appears to regulate the inflammatory response 
post-MI.   
Finally, the genes that are uniquely induced in Grem2-/- mice post-MI were 
isolated for their own analysis, the results of which are shown in Figure 38C. The 
genes that were uniquely present during the loss of Grem2 within the immune 
system process include thymocyte antigen-1 (Thy1), Vcam1, lymphocyte cell 
tyrosine kinase (Lck), and cell adhesion molecule-1 (Cadm1).  Of note, other 
genes that were specifically altered in Grem2-/- mice include cytotoxic T 
lymphocyte-associated protein 2α (Ctla2α), Cd4, Il-2 inducible T cell kinase (Itk), 
lymphotoxin B (Ltb), cannabinoid receptor 2 macrophage (Cnr2), chymase 1 
mast cell (Cma1), Ly6E, and T-cell interacting activating receptor myeloid cells 
(Tarm1), all of which fall under the unique pathway categories leukocyte 
activation, lymphocyte activation, and T cell activation.  Therefore, the changes 
to the inflammatory response post-MI from the loss of Grem2 could possibly be 
through the regulation of genes present within inflammatory cell populations 
themselves.  However, endothelial cell genes such as endothelial cell surface 
expressed chemotaxis and apoptosis regulator (Ecscr) and adhesion genes such 
as Alcam, Cadm1, and Vcam1 are also uniquely induced, corroborating with out 
previous data, where the regulation of the inflammatory response occurs at the 
level of inflammatory cell attachment and adhesion.   
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Discussion 
 High-throughout sequencing analysis such as RNA-seq provides the 
capability of determining pathway associations of Grem2 in an unbiased manner.  
To date, we have aligned our results to a mouse genome database and 
generated pathway analysis charts to see overall, the pathways that are 
significantly affected by the loss of Grem2.  Our current data confirm our previous 
work with more targeted approaches using qPCR, where the loss of Grem2 
resulted in profound changes to genes involved in inflammation and cell 
adhesion.   Furthermore, this analysis provided new gene targets, such as those 
that are involved in leukocyte and lymphocyte biology.  The next step in this 
analysis, will be to analyze the reads per kilo base per million mapped reads or 
RPKM values for genes present in both WT mice post-MI and Grem2-/- mice 
post-MI to determine if expression levels differ in the two models as well as 
conduct an analysis of genes that are uniquely present in WT mice post-MI as 
was done for the Grem2-/- mice.  This will provide important information regarding 
pathways that directly correlate with the level of Grem2 expression.  Future 
experiments confirming the results seen here, such as conducting qPCR for 
genes of interest will also be required.  
The advantage of conducting RNA-seq analysis is that it provides a 
breadth of information that could never be obtained at the targeted level.  In 
contrast, the information that can be obtained from such an analysis is limited by 
the alignment database utilized.  Current work focuses on using different 
alignment programs such as Tophat2 and the previously mentioned Kallisto in 
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order to confirm that the results being observed are not artifacts from the 
alignment.  Furthermore, there is a large amount of data that was not discussed 
in this chapter that requires further analysis.  The data presented here has been 
focused on pathways that are related to inflammatory response, however it would 
be interesting to investigate changes in other molecular pathways.   
Despite the fact that an unbiased approach such as high-throughput 
sequencing has confirmed the work described in previous chapters, it remains to 
be seen how the unique structure of Grem2 could confer to unique pathway 
associations. The results from this analysis could therefore be used to initiate a 
new hypothesis and series of experiments to move the research into new 
directions.  It is important to note that due to the plethora of data provided, there 
is still a lot to be done in order to gain further insight into the implications of the 
analysis.  Consequently, this analysis will serve as a starting point for future 
work.   
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CHAPTER IX 
 
SUMMARY AND CONCLUSION 
 
 
Summary 
In conclusion, our data support the following model of cardiac tissue 
repair: induction of pro-inflammatory cytokines such as Tnfα after MI initiates a 
transient inflammatory response, which is sustained by subsequent induction of 
Bmp2 by Tnfα.  Bmp2 increases the magnitude of inflammation through induction 
of pro-inflammatory cell adhesion membrane proteins in endothelial cells.  Grem2 
is then induced as part of a negative feedback loop to inhibit Bmp2’s pro-
inflammatory activity and act as a barrier of inflammation at the infarct border 
zone (Figure 39A, B).  To determine if Grem2 also plays a role during the later 
phases of recovery such as the proliferative and pro-fibrotic phases or to see if it 
has a direct role on cardiac remodeling, we conducted gene induction, 
histological, and flow cytometric analysis.  Our current data demonstrate that 
Grem2 may have complex roles in these processes. In order to gain further 
insight into the role of Grem2 in the recovery process after MI, we conducted 
RNA-seq analysis on our loss of function model 7 days post-MI.  Current high-
throughput sequencing data suggest that the loss of Grem2 leads to a specific 
up-regulation of certain immune processes as well as provides novel pathway 
associations that can be used to initiate future investigations.   
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Implications 
Here we provide evidence for a new mechanism that regulates the 
magnitude and extent of the inflammatory response after myocardial infarction.  
Specifically, we show that the BMP antagonist Grem2 is robustly and transiently 
induced after myocardial infarction during the late inflammatory phase and early 
proliferative phase of granulation tissue formation.  Genetic loss and gain of 
function approaches revealed that Grem2 a) controls the magnitude of the 
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inflammatory cell infiltration and, b) acts as a molecular barrier to limit infiltration 
of inflammatory cells in the relatively healthy cardiac tissue adjacent to the infarct 
border zone.  Consistent with this model, our data indicate that Grem2 
administration during the inflammatory phase of cardiac tissue repair decreases 
the number of inflammatory cells recruited to the infarct site after MI.  Our results 
further demonstrate that the anti-inflammatory effects of Grem2 depend, at least 
in part, on suppression of canonical BMP signaling through inhibition of 
Smad1/5/8 phosphorylation within ventricular tissue at the infarct border zone.  In 
agreement with this notion, administration of DMH1, a chemical inhibitor of 
canonical BMP signaling, rescued the inflammatory phenotype in Grem2-/- mice.   
The long history of either negative effects or no effects from using anti-
inflammatory treatments is due to targeting direct inflammatory mediators, 
however the success of the cyclosporine trial demonstrates that there is promise 
in utilizing inflammation as a therapeutic target (Piot et al., 2008a).  However, the 
benefits of cyclosporine use after MI could not be replicated in a larger clinical 
trial (Cung et al., 2015).  Here, we show that targeting a mediator of inflammation 
may prove to be more successful than targeting direct players in the 
inflammatory process.   
 
Limitations and Future directions 
Mouse models 
 
 The major limitations with this work involve the mouse models themselves 
and the model of myocardial infarction.  The mouse models described here 
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included the loss-of function or gene knock out mouse model which is 
constitutive and global and the gain- of function TG model, which is tissue 
specific but also constitutive.  This makes discerning specific roles of Grem2 
during the dynamic process of cardiac tissue repair, difficult.  Although we were 
able to test the effects of Grem2 directly by injecting mice with purified protein 
during the inflammatory phase of repair demonstrating that it plays a role during 
this process, the ability to determine how changes that occur during the 
inflammatory phase affects the later stages of recovery, including cardiac 
remodeling, requires further investigation. Future experiments utilizing our loss-
of-function mouse model, gain-of-function mouse model, or injection models for 
long-term studies (>21 days post-MI) in order to observe any long-term affects 
due to changes in Grem2 expression are therefore required.  Bone marrow 
transplantation studies would also be informative in determining the possible 
global effects of Grem2 loss-of-function on cells involved in the inflammatory 
phase of repair.  
Despite the fact the repair process following a myocardial infarction 
consists of distinct phases, these are actually intertwined, where a larger 
inflammatory response usually leads to a larger fibrotic response, thereby 
causing extensive cardiac remodeling.  Therefore, whether or not Grem2 has 
direct affects on these later stages of recovery or if the changes that occur are 
simply a result of the role of Grem2 on limiting the inflammatory phase is yet to 
be confirmed.  Future experiments utilizing inducible cell-specific knock-out 
models, would be useful in both confirming the cellular source of Grem2 in the 
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context of cardiac repair as well as well as tease apart roles of Grem2 during 
early versus late phases of cardiac repair.   
 The model of myocardial infarction in the studies described here was a 
permanent ligation model, where the LAD coronary artery is permanently ligated 
or closed.  Since the mice that undergo the procedure are young and without the 
co-morbidities usually associated with a myocardial infarction in human patients, 
they are able to survive the surgery.  Therefore the model is more akin to those 
that suffer a massive heart attack resulting from a major artery being blocked and 
that do not survive.  However another model exists that is more similar to the 
clinic, and that is the ischemia/reperfusion (I/R) model.  In this model the LAD 
coronary artery is also ligated, but after several minutes re-opened, allowing 
blood to flow through.  Utilization of such a model would also provide information 
regarding infarct size in our experimental groups. We did not use this model in 
our studies due to the fact that the re-oxygenation of cells leads to a more 
complex inflammatory response, the infarct size in a permanent ligation model is 
more reproducible, and because mice tolerate permanent ligation better than I/R.   
 In lieu of these limitations, future experiments could include injecting mice 
with Grem2 at a later stage of the recovery process, i.e. days 5-7 post-MI, to 
determine if there are changes to cell populations, gene expression analysis, or 
functional recovery.  Based on the data described in CHAPTER VII however it is 
unlikely that Grem2 will have a dramatic effect.  Future experiments could also 
include the use of 60 minute I/R instead of permanent ligation as a model of MI in 
order determine if the inflammatory phenotype is due to changes to infarct size 
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as well as determine if the changes to inflammation seen post-MI are also 
present during the recovery process of this type of injury.    
 Due to the fact that the work described here illustrates a positive role for 
Grem2 in cardiac tissue repair, and previous work in the lab demonstrates a 
positive role for Wnt10b in cardiac repair (Paik et al., 2015), it would be beneficial 
to test the repair process when both BMP and Wnt pathways are favorably 
modulated.  It is possible that the overexpression of Grem2 to limit the 
inflammatory response, when combined with Wnt10b overexpression to induce 
arteriogenesis and limits fibrosis as was previously described, will further 
optimize recovery.   
Although therapeutic potential was illustrated through the administration of 
proteins following a myocardial infarction as described in previous chapters, this 
was done through IP.   Despite the fact that our data indicated that these proteins 
do in fact reach the heart, it is still unclear if we are reaching maximal efficiency.  
To address this issue, more optimal delivery methods and evaluation of protein 
bioavailability will need to be tested. 
 
Molecular Mechanisms 
Our data thus far have demonstrated that BMP2 increases the pro-
inflammatory activity of TNFα through activation of canonical BMP signaling.  
However, previous reports have demonstrated that BMP2 is able to activate non-
canonical BMP signaling and NFκB signaling (Csiszar et al., 2005, 2006; Helbing 
et al., 2011).  Therefore, there is a need for future experiments aimed at testing if 
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BMP activates NFκB in the context of cardiac repair.  These could include 
injecting Grem2-/- mice with an NFκB inhibitor in order to see what phenotypes 
are rescued, conducting histological analysis in order to measure levels of 
nuclear NFκB in each of the different mouse models, and western blot analysis 
with tissue isolated post-MI to measure levels of P-Smad1/5/8 and NFκB 
signaling components.  The molecular mechanism could also be investigated 
using endothelial cell in vitro models, and include conducting BRE-luc and NFκB-
luc analysis and western blot analyses after treatment with exogenous TNFα, 
BMP2, and the two together.   
Due to the unique structure of Grem2 as well as the limited number of 
studies conducted on the molecular action of Grem2, it remains possible that 
Grem2 could have a unique binding capacity with BMP ligands, which could also 
lead to a unique mode of BMP antagonism.  The Hatzopoulos laboratory has 
previously shown that Grem2 promotes the activation of non-canonical BMP 
signaling components such as JNK in cardiomyocytes derived from mouse 
embryonic stem cells (Tanwar et al., 2014).  Whether Grem2 activates non-
canonical BMP signaling during cardiac tissue repair is yet to be determined.  
Future experiments could explore if JNK activation occurs after experimental MI 
and if changes to Grem2 expression lead to changes in this activation.  Through 
collaborative efforts, we have access to several mutant proteins that contain a 
point mutation within the binding domain of Grem2.  Therefore, future analysis 
could be conducted in order to assess the ability of these proteins to not only 
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inhibit canonical versus non-canonical BMP signaling in our system, but if binding 
of Grem2 to the BMP2 ligand is required for its anti-inflammatory activity.   
Our current analysis also does not reveal if Grem2 activity is dependent 
upon certain BMP receptors or ligands.  Future research could be aimed at 
determining the molecular basis for the biochemical and biological activities of 
Grem2. 
 The constitutive nature of the Grem2 loss of function mouse model is a 
weakness in the context of cardiac repair.  However the fact that Grem2-/- is 
global and the mice are viable is in fact beneficial for the use of investigations 
into a wide range of disease states.  
  
Conclusions 
Cardiovascular diseases remain to be the number one cause of death in 
both men and women around the world despite the many advances that have 
been made in the field.  An acute cardiac injury such as a heart attack or 
myocardial infarction contributes to the onset of heart failure, a disease with a 
survival rate lower than any cancer (Braunwald, 2015; McMurray, 2010).  Current 
therapies such as angiotensin converting enzyme (ACE) inhibitors and Beta-
blockers are aimed at regaining blood flow as well as decreasing workload on the 
damaged heart.  However, it is important to note that most of these treatments 
also have some sort of anti-inflammatory effect, underscoring the importance of 
regulating the inflammatory phase of recovery (McMurray, 2010).  One of the 
major hindrances in the field is that not much is known about the molecules that 
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help generate a barrier and limit the magnitude of the inflammatory response.  
We have data to suggest that we have in fact identified one such molecule.  
Utilizing unique mouse models, we have been able to determine a novel role of a 
relatively unstudied protein in the context of cardiac repair. Therefore Grem2 has 
demonstrated to be a molecule with great therapeutic potential.   
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TABLES 
 
Table 1. Primer Sequences used in qPCR analyses and Grem2-/- mouse genotyping 
Mouse primers qPCR: 
Ang-1 
 
Anp(Nppa) 
 
Axin2 
 
Bmp2 
 
5’ 
3’ 
5’ 
3’ 
5’ 
3’ 
5’ 
3’ 
CCACCATGCTTGAGATAGGAACC 
CTGTGAGTAGGCTCGGTTCCC 
TTTCAAGAACCTCGTAGACCACCTG 
AAGCTGTTGCAGCCTAGTCCACTCT 
CCAGAAGATCACAAAGAGCCAAAGA 
CTCAGTCGATCCTCTCCACTTTGC 
GCTGTCTTCTAGTGTTGCTGCTT 
GGGACAGAACTTAAATTGAAGAAGA 
Bmp4 5’ 
3’ 
ATGATTCCTGGTAACCGAATGCTG 
CTTCGTGATGGAAACTCCTC 
Bmp6 5’ 
3’ 
AACGCCCTGTCCAATGACG 
ACTCTTGCGGTTCAAGGAGTG 
Bmp7 5’ 
3’ 
ACGGACAGGGCTTCTCCTAC 
ATGGTGGTATCGAGGGTGGAA 
Bmp10 
 
Bmpr2 
 
Bnp (Nppb) 
 
β-mhc 
 
5’ 
3’ 
5’ 
3’ 
5’ 
3’ 
5’ 
3’ 
AAATTCGCCACAGACCGGAC 
GGTGAGGGATAGACACATTGAAG 
CTCAGAATCAAGAACGGCTGTG 
CAACTGGACGCTGATCCAAGG 
ATGCATCTCCTGAAGGTGCTG 
GTGCTGCCTTGAGACCGAA 
CCAACTATGCTGGAGCTGGATG 
CTTCTTGAACTCCATTCTGGAGAG 
Chordin 
 
Pro-Collagen Ia1 
 
5’ 
3’ 
5’ 
3’ 
CTAGGAAATGGCTCCCTTATCTATC 
TGTAAGTGACAATGTGTATCCAAGG 
GCTAACGTGGTTCGTGACCGTG 
GGTCAGCTGGATAGCGACATC 
Dand5 5’ 
3’ 
CTGTCCTTTGTTCAGGTGATCTC 
CCGAGGGGAGGCTAATTGG 
Dan 5’ 
3’ 
CTAGGACAATGCTTCAGTTACAGC 
CTTCAGATCTCCATGACAACCAG 
E-selectin 
 
Fsp-1 
 
5’ 
3’ 
5’ 
3’ 
GAGCACAGCTTGGTACTACAATGC 
GGTGGCACTTGCAGGTGTAAC 
TCAGGCAAAGAGGGTGACAAG 
AGGCAGCTCCCTGGTCAGT 
Gapdh 
 
Grem1 
5’ 
3’ 
5’ 
3’ 
CTCACTCAAGATTGTCAGCAATG 
GAGGGAGATGCTCAGTGTTGG 
GGAA/TTCTGCAAGCCCAAGAAGTTCACCAC 
CGGGA/TCCTCTGTCCCGTTTGCCATCAC 
Grem2(1) 5’ 
3’ 
CCTGTCATTCACAGAGAGGA 
CATTCGAGCTCTACGATGAC 
Icam1 
 
5’ 
3’ 
GGAGACGCAGAGGACCTTAACAG 
CATCTCCTGTTTGACAGACTTCACC  
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Id2 
 
Il-8 
5’ 
3’ 
5’ 
3’ 
CGACCCGATGAGTCTGCTCTACAAC 
GTGTTCTCCTGGTGAAATGGCTGATAAC 
CACCTCAAGAACATCCAGAGCT  
CAAGCAGAACTGAACTACCATCG 
Il-10 5’ 
3’ 
GACCAGCTGGACAACATACTGC 
CCAGCAGACTCAATACACACTGC 
Il-1β 
 
Mcp-1 (Ccl-2) 
 
Mmp9 
 
5’ 
3’ 
5’ 
3’ 
5’ 
3’ 
TTTGACCTGGGCTGTCCTGATG 
CATATGGGTCCGACAGCACGAG 
ACCTGCTGCTACTCATTCACC 
CACTGTCACACTGGTCACTCC 
CCCGCTGTATAGCTACCTCGAGGGC 
AGCGTTGCAGGCAGGGCTGG 
Noggin 
 
5’ 
3’ 
GCCAGCACTATCTACACATCC 
GCGTCTCGTTCAGATCCTTCTC 
αSma 
 
5’ 
3’ 
CCACGAAACCACCTATAACAGCATC 
GTCGTATTCCTGTTTGCTGATCCAC 
Sost 5’ 
3’ 
AGCCTTCAGGAATGATGCCAC 
CTTTGGCGTCATAGGGATGGT 
Tgfβ1 5’ 
3’ 
AGATTAAAATCAAGTGTGGAGCAAC 
GTCCTTCCTAAAGTCAATGTACAGC 
Tnfα 
 
Twsg1 
 
5’ 
3’ 
5’ 
3’ 
CTACTGAACTTCGGGGTGATCGGTCC 
CCTTCATCTTCCTCCTTATCTCTCATGCC 
TCTAGCCTCCCTGACGTTCC 
CACATACCGACACAGTCGC 
Vcam1 
 
Ve-cadherin 
 
Vimentin 
 
Wnt4 
 
Wnt10b 
5’ 
3’ 
5’ 
3’ 
5’ 
3’ 
5’ 
3’ 
5’ 
3’ 
 
AGAGAAACCATTTATTGTTGACATCTCCC 
CAAGTGGCCCACTCATTTTAATTACTGG 
CACTATCACAGTGATTACCTTGCTG 
GTCATAATCGATGTCAGAGTCGG 
GGTACAAGTCCAAGTTTGCTGACCT 
CATTGAGCAGATCTTGGTATTCACG 
CTCCTGCGAGGTAAAGACGTG 
AGTATCTTTTGGGGTAGGTGGTG 
AGAAGTTCTCTCGGGATTTCTTG 
CAAAGTAAACCAGCTCTCCAG 
Human primers: 
BMP2 
 
 
5’ 
3’ 
 
ACCCGCTGTCTTCTAGCGT 
TTTCAGGCCGAACATGCTGAG 
E-SELECTIN 5’ 
3’ 
GCTGGACTCTCCCTCCTGACATTAGC 
CATAAAGGCATCTGGCATAGTAGGCAAG 
GAPDH 5’ 
3’ 
AAGGTGAAGGTCGGAGTCAAC 
GGGGTCATTGATGGCAACAATA 
GREM2 5’ 
3’ 
ATCCCCTCGCCTTACAAGGA 
TCTTGCACCAGTCACTCTTGA 
ID2 5’ 
3’ 
GCATCCCCCAGAACAAGAAGGTGAG 
CGCTTATTCAGCCACACAGTGCTTTG 
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Genotyping Primers: 
Primer 1 
Primer 2 
Primer 3 
Primer 4 
Primer 5 
Primer 6 
5’ 
3’ 
3’ 
5’ 
5’ 
3’ 
CTGTGCAGCAGAGAAAGCTG 
TGGCAATGTACCTCATCTCA 
CTGTCCATCTGCACGAGACT 
TCTGGTACCCACGAGGACAAGC 
GTCTGAGTAGGTGTCATTCTA 
CACAGATCACTCGATGCTCT 
 
1. Suzuki D et al. (2012). BMP2 differentially regulates the expression of Gremlin1 and 
Gremlin2, the negative regulators of BMP function, during osteoblast differentiation. 
Calcif. Tissue. Int. 91, 88–96. 
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Table 4. RNA-seq analysis comparing WT and Grem2-/- mice at baseline.	  	  	  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Definition Symbol fold-Grem2KO_vs_WT
histone	cluster	1,	H4m	[Source:MGI	Symbol;Acc:MGI:2448441] Hist1h4m -8.404752002
ribosomal	protein	S3A2	[Source:MGI	Symbol;Acc:MGI:3642853] Rps3a2 -8.268432785
ribosomal	protein	S3A3	[Source:MGI	Symbol;Acc:MGI:3643406] Rps3a3 -3.430341307
glycerophosphodiester	phosphodiesterase	domain	containing	3	[Source:MGI	Symbol;Acc:MGI:1915866] Gdpd3 -2.932662122
immunoglobulin	kappa	joining	4	[Source:MGI	Symbol;Acc:MGI:1316692] Igkj4 -2.411175729
histone	cluster	1,	H4i	[Source:MGI	Symbol;Acc:MGI:2448432] Hist1h4i 2.010354801
myomesin	1	[Source:MGI	Symbol;Acc:MGI:1341430] Myom1 2.086813383
solute	carrier	family	27	(fatty	acid	transporter),	member	2	[Source:MGI	Symbol;Acc:MGI:1347099] Slc27a2 2.152859496
ribosomal	protein	L21,	pseudogene	15	[Source:MGI	Symbol;Acc:MGI:3705426] Rpl21-ps15 2.827529748
tropomyosin	3,	related	sequence	7	[Source:MGI	Symbol;Acc:MGI:99705] Tpm3-rs7 2.942246171
chemokine	(C-X-C	motif)	ligand	14	[Source:MGI	Symbol;Acc:MGI:1888514] Cxcl14 3.990014607
PAXIP1	associated	glutamate	rich	protein	1B	[Source:MGI	Symbol;Acc:MGI:5141883] Pagr1b 5.912658163
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